<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34676194</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2296-2565</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Frontiers in public health</Title><ISOAbbreviation>Front Public Health</ISOAbbreviation></Journal><ArticleTitle>Emerging and Re-emerging Vector-Borne Infectious Diseases and the Challenges for Control: A Review.</ArticleTitle><Pagination><StartPage>715759</StartPage><MedlinePgn>715759</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">715759</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fpubh.2021.715759</ELocationID><Abstract><AbstractText>Vector-borne emerging and re-emerging diseases pose considerable public health problem worldwide. Some of these diseases are emerging and/or re-emerging at increasing rates and appeared in new regions in the past two decades. Studies emphasized that the interactions among pathogens, hosts, and the environment play a key role for the emergence or re-emergence of these diseases. Furthermore, social and demographic factors such as human population growth, urbanization, globalization, trade exchange and travel and close interactions with livestock have significantly been linked with the emergence and/or re-emergence of vector-borne diseases. Other studies emphasize the ongoing evolution of pathogens, proliferation of reservoir populations, and antimicrobial drug use to be the principal exacerbating forces for emergence and re-emergence of vector-borne infectious diseases. Still other studies equivocally claim that climate change has been associated with appearance and resurgence of vector-borne infectious diseases. Despite the fact that many important emerging and re-emerging vector-borne infectious diseases are becoming better controlled, our success in stopping the many new appearing and resurging vector-borne infectious diseases that may happen in the future seems to be uncertain. Hence, this paper reviews and synthesizes the existing literature to explore global patterns of emerging and re-emerging vector-borne infections and the challenges for their control. It also attempts to give insights to the epidemiological profile of major vector-borne diseases including Zika fever, dengue, West Nile fever, Crimean-Congo hemorrhagic fever, Chikungunya, Yellow fever, and Rift Valley fever.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Chala and Hamde.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chala</LastName><ForeName>Bayissa</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Applied Biology, School of Applied Natural Science, Adama Science and Technology University, Adama, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamde</LastName><ForeName>Feyissa</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Applied Biology, School of Applied Natural Science, Adama Science and Technology University, Adama, Ethiopia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Public Health</MedlineTA><NlmUniqueID>101616579</NlmUniqueID><ISSNLinking>2296-2565</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065632" MajorTopicYN="Y">Chikungunya Fever</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021821" MajorTopicYN="Y">Communicable Diseases, Emerging</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004199" MajorTopicYN="N">Disease Vectors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000079426" MajorTopicYN="Y">Vector Borne Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015004" MajorTopicYN="Y">Yellow Fever</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071244" MajorTopicYN="Y">Zika Virus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071243" MajorTopicYN="Y">Zika Virus Infection</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">climate change</Keyword><Keyword MajorTopicYN="N">emerging infectious diseases</Keyword><Keyword MajorTopicYN="N">re-emerging infectious diseases</Keyword><Keyword MajorTopicYN="N">vector-borne infectious diseases</Keyword><Keyword MajorTopicYN="N">zoonotic diseases</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34676194</ArticleId><ArticleId IdType="pmc">PMC8524040</ArticleId><ArticleId IdType="doi">10.3389/fpubh.2021.715759</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gubler DJ. The global threat of emergent/re-emergent vector-borne diseases. In: Atkinson PW. editors. Vector Biology, Ecology and Control. Dordrecht: Springer; (2010).</Citation></Reference><Reference><Citation>Savi S, Vidic B, Grgi Z, Potkonjak A, Spasojevic L. Emerging vector-borne diseases incidence through vectors. Front Public Health. (2014) 2:267. 10.3389/fpubh.2014.00267</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2014.00267</ArticleId><ArticleId IdType="pmc">PMC4251170</ArticleId><ArticleId IdType="pubmed">25520951</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvell CD, Mitchell CE, Ward JR, Altizer S, Dobson AP, Ostfeld RS, et al. . Climate warming and disease risks for terrestrial and marine biota. Science. (2002) 296:2158&#x2013;62. 10.1126/science.1063699</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1063699</ArticleId><ArticleId IdType="pubmed">12077394</ArticleId></ArticleIdList></Reference><Reference><Citation>IPCC . Intergovernmental Panel on Climate Change the Physical Science Basis. Cambridge: Cambridge University Press; (2007).</Citation></Reference><Reference><Citation>Watson RT, Zinyowera MC, Moss RH. Climate Change; Impacts, Adaptations and Mitigation of Climate Change: Scientific-Technical Analysis. Contribution of Working Group II to the Second Assessment Report of the Intergovernmental Panel on Climate Change. Cambridge: Cambridge University Press; (1995).</Citation></Reference><Reference><Citation>Chu K, Mott KE, Rey L, Hunter J, Adekolu-John E. Parasitic Diseases in Water Resources Development: the Need for Intersectoral Negotiation. Geneva: WHO; (1993).</Citation></Reference><Reference><Citation>Kibret S, Lautze J, McCartney M, Nhamo L, Wilson GG. Malaria and large dams in sub-Saharan Africa: future impacts in a changing climate. Malar J. (2016) 15:448. 10.1186/s12936-016-1498-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12936-016-1498-9</ArticleId><ArticleId IdType="pmc">PMC5011356</ArticleId><ArticleId IdType="pubmed">27592590</ArticleId></ArticleIdList></Reference><Reference><Citation>Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet. (2006) 368:1106&#x2013;18. 10.1016/S0140-6736(06)69440-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(06)69440-3</ArticleId><ArticleId IdType="pubmed">16997665</ArticleId></ArticleIdList></Reference><Reference><Citation>Chala B, Torben W. An epidemiological trend of urogenital schistosomiasis in Ethiopia. Front Public Health. (2018) 6:60. 10.3389/fpubh.2018.00060</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2018.00060</ArticleId><ArticleId IdType="pmc">PMC5844936</ArticleId><ArticleId IdType="pubmed">29556490</ArticleId></ArticleIdList></Reference><Reference><Citation>Morens DM, Folkers GK, Fauci AS. Emerging infections: a perpetual challenge. Lancet Infect Dis. (2008) 8:710&#x2013;9. 10.1016/S1473-3099(08)70256-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(08)70256-1</ArticleId><ArticleId IdType="pmc">PMC2599922</ArticleId><ArticleId IdType="pubmed">18992407</ArticleId></ArticleIdList></Reference><Reference><Citation>Carruthers VB, Cotter PA, Kumamoto CA. Microbial pathogenesis: mechanisms of infectious disease. Cell Host Microbe. (2007) 2:214&#x2013;9. 10.1016/j.chom.2007.09.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2007.09.007</ArticleId><ArticleId IdType="pmc">PMC2663044</ArticleId><ArticleId IdType="pubmed">18005739</ArticleId></ArticleIdList></Reference><Reference><Citation>IPCC . Climate Change 2014: Impacts, Adaptation, and Vulnerability. Part A: Global and Sectoral Aspects (eds Field CB, Barros VR, Dokken DJ, Mach KJ, Mastrandrea MD, Bilir TE, Monalisa C, Ebi KL, Estrada YO, Genova RC, Girma B, Kissel ES, Levy AN, MacCracken S, Mastrandrea PR, White LL.), Cambridge University Press; (2014).</Citation></Reference><Reference><Citation>Brady OJ, Johansson MA, Guerra CA, Bhatt S, Golding N, Pigott DM, et al. . Modeling adult Aedes aegypti and Aedes albopictus survival at different temperatures in laboratory and field settings. Parasit Vectors. (2013) 6:351. 10.1186/1756-3305-6-351</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1756-3305-6-351</ArticleId><ArticleId IdType="pmc">PMC3867219</ArticleId><ArticleId IdType="pubmed">24330720</ArticleId></ArticleIdList></Reference><Reference><Citation>Mellor PS, Leake CJ. Climatic and geographic influences on arboviral infections and vectors. Rev Sci Tech. (2000) 19:41&#x2013;54. 10.20506/rst.19.1.1211</Citation><ArticleIdList><ArticleId IdType="doi">10.20506/rst.19.1.1211</ArticleId><ArticleId IdType="pubmed">11189725</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian HY, Zhou S, Dong L, VanBoeckel TP, Cui YJ, Wu YR, et al. . Avian influenza H5N1 viral and bird migration networks in Asia. Proc Natl Acad Sci USA. (2015) 112:172&#x2013;7. 10.1073/pnas.1405216112</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1405216112</ArticleId><ArticleId IdType="pmc">PMC4291667</ArticleId><ArticleId IdType="pubmed">25535385</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisen WK, Fang Y, Martinez VM. Effects of temperature on the transmission of West Nile Virus by Culex tarsalis (Diptera: Culicidae). J Med Entomol. (2006) 43:309&#x2013;17. 10.1093/jmedent/43.2.309</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jmedent/43.2.309</ArticleId><ArticleId IdType="pubmed">16619616</ArticleId></ArticleIdList></Reference><Reference><Citation>Keesing F, Belden LK, Daszak P, Dobson A, Harvell CD, Holt RD, et al. . Impacts of biodiversity on the emergence and transmission of infectious diseases. Nature. (2010) 468: 647&#x2013;52. 10.1038/nature09575</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09575</ArticleId><ArticleId IdType="pmc">PMC7094913</ArticleId><ArticleId IdType="pubmed">21124449</ArticleId></ArticleIdList></Reference><Reference><Citation>Medlock JM, Leach SA. Effect of climate change on vector-borne disease risk in the UK. Lancet Infect Dis. (2015) 15:721&#x2013;30. 10.1016/S1473-3099(15)70091-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(15)70091-5</ArticleId><ArticleId IdType="pubmed">25808458</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogden NH, Lindsay LR. Effects of climate and climate change on vectors and vector-borne diseases: ticks are different. Trends Parasitol. (2016) 32:646&#x2013;56. 10.1016/j.pt.2016.04.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pt.2016.04.015</ArticleId><ArticleId IdType="pubmed">27260548</ArticleId></ArticleIdList></Reference><Reference><Citation>Lafferty KD. The ecology of climate change and infectious diseases. Ecology. (2009) 90:888&#x2013;900. 10.1890/08-0079.1</Citation><ArticleIdList><ArticleId IdType="doi">10.1890/08-0079.1</ArticleId><ArticleId IdType="pubmed">19449681</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogden NH, Radojevic M, Wu X, Duvvuri VR, Leighton PA, Wu J, et al. . Estimated effects of projected climate change on the basic reproductive number of the tick vector of Lyme disease Ixodes scapularis. Environ Health Perspect. (2014) 122:631&#x2013;8. 10.1289/ehp.1307799</Citation><ArticleIdList><ArticleId IdType="doi">10.1289/ehp.1307799</ArticleId><ArticleId IdType="pmc">PMC4050516</ArticleId><ArticleId IdType="pubmed">24627295</ArticleId></ArticleIdList></Reference><Reference><Citation>Swei A, Couper LI, Coffey LL, Kapan D, Bennett S. Patterns, drivers, and challenges of vector-borne disease emergence. Vector Borne Zoonotic Dis. (2020) 20:159&#x2013;70. 10.1089/vbz.2018.2432</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/vbz.2018.2432</ArticleId><ArticleId IdType="pmc">PMC7640753</ArticleId><ArticleId IdType="pubmed">31800374</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry BD, Grace D, Sones K. Current drivers and future directions of global lives to directions of global livestock disease dynamics. Proc Natl Acad Sci USA. (2011) 110:20871&#x2013;7. 10.1073/pnas.1012953108</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1012953108</ArticleId><ArticleId IdType="pmc">PMC3876220</ArticleId><ArticleId IdType="pubmed">21576468</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones BA, Grace D, Kock R, Alonso S, Rushton J, Said MY, et al. . Zoonosis emergence linked to agricultural intensification and environmental change. Proc Natl Acad Sci USA. (2013) 110:8399&#x2013;404. 10.1073/pnas.1208059110</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1208059110</ArticleId><ArticleId IdType="pmc">PMC3666729</ArticleId><ArticleId IdType="pubmed">23671097</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong MX, Hansen A, Hanson-Easey S, Cameron S, Xiang J, Liu Q, et al. . Infectious diseases, urbanization and climate change: challenges in future China. Int J Environ Res Public Health. (2015) 12:11025&#x2013;36. 10.3390/ijerph120911025</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph120911025</ArticleId><ArticleId IdType="pmc">PMC4586659</ArticleId><ArticleId IdType="pubmed">26371017</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss RA, McMichael AJ. Social and environmental risk factors in the emergence of infectious diseases. Nat Med. (2004) 10:S70&#x2013;6. 10.1038/nm1150</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1150</ArticleId><ArticleId IdType="pmc">PMC7095886</ArticleId><ArticleId IdType="pubmed">15577934</ArticleId></ArticleIdList></Reference><Reference><Citation>Lashley FR. Emerging infectious disease: vulnerabilities, contributing factors and approaches. Expert Rev Anti Infect Ther. (2004) 2:299&#x2013;316. 10.1586/14787210.2.2.299</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14787210.2.2.299</ArticleId><ArticleId IdType="pubmed">15482195</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcais A, Abel L, Casanova JL. Human genetics of infectious diseases: between proof of principle and paradigm. J Clin Invest. (2009) 119:2506&#x2013;14. 10.1172/JCI38111</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI38111</ArticleId><ArticleId IdType="pmc">PMC2735901</ArticleId><ArticleId IdType="pubmed">19729848</ArticleId></ArticleIdList></Reference><Reference><Citation>Nii-Trebi NI. Emerging and neglected infectious diseases: insights, advances, and challenges. Biomed Res Int. (2017) 2017:5245021. 10.1155/2017/5245021</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/5245021</ArticleId><ArticleId IdType="pmc">PMC5327784</ArticleId><ArticleId IdType="pubmed">28286767</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasconcelos PF, Monath TP. Yellow fever remains a potential threat to public health. Vector Borne Zoonotic Dis. (2016) 16:566&#x2013;7. 10.1089/vbz.2016.2031</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/vbz.2016.2031</ArticleId><ArticleId IdType="pubmed">27400066</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubler DJ. Dengue, urbanization and globalization: the unholy trinity of the 21st Century. Trop Med Health. (2011) 39:3&#x2013;11. 10.2149/tmh.2011-S05</Citation><ArticleIdList><ArticleId IdType="doi">10.2149/tmh.2011-S05</ArticleId><ArticleId IdType="pmc">PMC3317603</ArticleId><ArticleId IdType="pubmed">22500131</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe R, Barcellos C, Brasil P, Cruz OG, Hon&#xf3;rio NA, Kuper H, et al. . The Zika virus epidemic in Brazil: from discovery to future implications. Int J Environ Res Public Health. (2018) 15:E96. 10.3390/ijerph15010096</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph15010096</ArticleId><ArticleId IdType="pmc">PMC5800195</ArticleId><ArticleId IdType="pubmed">29315224</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassell JM, Begon M, Ward MJ, F&#xe8;vre EM. Urbanization and disease emergence: dynamics at the wildlife&#x2013;livestock&#x2013;human interface. Trends Ecolo Evolution. (2017) 32:55&#x2013;67. 10.1016/j.tree.2016.09.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tree.2016.09.012</ArticleId><ArticleId IdType="pmc">PMC5214842</ArticleId><ArticleId IdType="pubmed">28029378</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsay SW, Wilson A, Golding N, Scott TW, Takken W. Improving the built environment in urban areas to control Aedes aegypti-borne diseases. Bull World Health Organ. (2017) 95:607&#x2013;8. 10.2471/BLT.16.189688</Citation><ArticleIdList><ArticleId IdType="doi">10.2471/BLT.16.189688</ArticleId><ArticleId IdType="pmc">PMC5537749</ArticleId><ArticleId IdType="pubmed">28804174</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearce JC, Learoyd TP, Langendorf BJ, Logan JG. Japanese encephalitis: the vectors, ecology and potential for expansion. J Travel Med. (2018) 25:S16&#x2013;26. 10.1093/jtm/tay009</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jtm/tay009</ArticleId><ArticleId IdType="pubmed">29718435</ArticleId></ArticleIdList></Reference><Reference><Citation>Karesh W.B. Ecology of zoonoses: natural and unnatural histories. Lancet. (2012) 380:1936&#x2013;45. 10.1016/S0140-6736(12)61678-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(12)61678-X</ArticleId><ArticleId IdType="pmc">PMC7138068</ArticleId><ArticleId IdType="pubmed">23200502</ArticleId></ArticleIdList></Reference><Reference><Citation>McFarlane RA, Sleigh AC, McMichael AJ. Land-use change and emerging infectious disease on an island continent. Int J Environ Res Public Health. (2013) 10:2699&#x2013;719. 10.3390/ijerph10072699</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph10072699</ArticleId><ArticleId IdType="pmc">PMC3734451</ArticleId><ArticleId IdType="pubmed">23812027</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottdenker NL, Streicker DG, Faust CL, Carroll CR. Anthropogenic land use change and infectious diseases: a review of the evidence. Ecohealth. (2014) 11:619&#x2013;32. 10.1007/s10393-014-0941-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10393-014-0941-z</ArticleId><ArticleId IdType="pubmed">24854248</ArticleId></ArticleIdList></Reference><Reference><Citation>Kock RA. Vertebrate reservoirs and secondary epidemiological cycles of vector-borne diseases. Rev Sci Tech. (2015) 34:151&#x2013;63. 10.20506/rst.34.1.2351</Citation><ArticleIdList><ArticleId IdType="doi">10.20506/rst.34.1.2351</ArticleId><ArticleId IdType="pubmed">26470455</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah HA, Huxley P, Elmes J, Murray KA. Agricultural land-uses consistently exacerbate infectious disease risks in Southeast Asia. Nat Commun. (2019) 10:4299. 10.1038/s41467-019-12333-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-12333-z</ArticleId><ArticleId IdType="pmc">PMC6754503</ArticleId><ArticleId IdType="pubmed">31541099</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohr JR, Barrett CB, Civitello DJ, Craft ME, Delius B, DeLeo GA, et al. . Emerging human infectious diseases and the links to global food production. Nat Sustain. (2019) 2:445&#x2013;56. 10.1038/s41893-019-0293-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41893-019-0293-3</ArticleId><ArticleId IdType="pmc">PMC7091874</ArticleId><ArticleId IdType="pubmed">32219187</ArticleId></ArticleIdList></Reference><Reference><Citation>Pepin M, Bouloy M, Bird BH, Kemp A, Paweska J. Rift valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. Vet Res. (2010) 41:61. 10.1051/vetres/2010033</Citation><ArticleIdList><ArticleId IdType="doi">10.1051/vetres/2010033</ArticleId><ArticleId IdType="pmc">PMC2896810</ArticleId><ArticleId IdType="pubmed">21188836</ArticleId></ArticleIdList></Reference><Reference><Citation>GBD 2017 Causes of Death Collaborators . Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. (2018) 392:1736&#x2013;88. 10.1016/S0140-6736(18)32203-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)32203-7</ArticleId><ArticleId IdType="pmc">PMC6227606</ArticleId><ArticleId IdType="pubmed">30496103</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasetsirikul S, Buranapong J, Srituravanich W, Kaewthamasorn M. Pimpin A. The development of malaria diagnostic techniques: a review of the approaches with focus on dielectrophoretic and magnetophoretic methods. Malar J. (2016) 15:358. 10.1186/s12936-016-1400-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12936-016-1400-9</ArticleId><ArticleId IdType="pmc">PMC4942956</ArticleId><ArticleId IdType="pubmed">27405995</ArticleId></ArticleIdList></Reference><Reference><Citation>Siraj AS, Santos-Vega M, Bouma MJ, Yadeta D, Ruiz Carrascal D, Pascual M. Altitudinal changes in malaria incidence in highlands of Ethiopia and Colombia. Science. (2014) 343:1154&#x2013;8. 10.1126/science.1244325</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1244325</ArticleId><ArticleId IdType="pubmed">24604201</ArticleId></ArticleIdList></Reference><Reference><Citation>Amek N, Bayoh N, Hamel M, Lindblade KA, Gimnig JE, Odhiambo F, et al. . Spatial and temporal dynamics of malaria transmission in rural Western Kenya. Parasit Vectors. (2012) 5:86. 10.1186/1756-3305-5-86</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1756-3305-5-86</ArticleId><ArticleId IdType="pmc">PMC3464956</ArticleId><ArticleId IdType="pubmed">22541138</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . World Malaria Report 2017. Geneva: World Health Organization; (2017).</Citation></Reference><Reference><Citation>Laughlin CA, Morens DM, Cassetti MC, Costero-Saint Denis A, San Martin JL, Whitehead SS, et al. . Dengue research opportunities in the Americas. J Infect Dis. (2012) 206:1121&#x2013;7. 10.1093/infdis/jis351</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jis351</ArticleId><ArticleId IdType="pmc">PMC3499110</ArticleId><ArticleId IdType="pubmed">22782946</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilder-Smith A, Gubler DJ. Geographic expansion of dengue: the impact of international travel. Med Clin North Am. (2008) 92:1337&#x2013;90. 10.1016/j.mcna.2008.07.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcna.2008.07.002</ArticleId><ArticleId IdType="pubmed">19061757</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambrechts L, Scott TW, Gubler DJ. Consequences of the expanding global distribution of Aedes albopictus for dengue virus transmission. PLoS Negl Trop Dis. (2010) 4:e646. 10.1371/journal.pntd.0000646</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0000646</ArticleId><ArticleId IdType="pmc">PMC2876112</ArticleId><ArticleId IdType="pubmed">20520794</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. . The global distribution and burden of dengue. Nature. (2013) 496:504&#x2013;7. 10.1038/nature12060</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12060</ArticleId><ArticleId IdType="pmc">PMC3651993</ArticleId><ArticleId IdType="pubmed">23563266</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady OJ, Smith DL, Scott TW, Hay SI. Dengue disease outbreak definitions are implicitly variable. Epidemics. (2015) 11:92&#x2013;102. 10.1016/j.epidem.2015.03.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.epidem.2015.03.002</ArticleId><ArticleId IdType="pmc">PMC4429239</ArticleId><ArticleId IdType="pubmed">25979287</ArticleId></ArticleIdList></Reference><Reference><Citation>Musso D, Cao-Lormeau VM, Gubler DJ. Zika virus: following the path of dengue and chikungunya? Lancet. (2015) 386:243&#x2013;4. 10.1016/S0140-6736(15)61273-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(15)61273-9</ArticleId><ArticleId IdType="pubmed">26194519</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin X, Lin M, Shu J. Dengue fever in China: an emerging problem demands attention. Emerg Microbes Infect. (2015) 4:e3. 10.1038/emi.2015.3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emi.2015.3</ArticleId><ArticleId IdType="pmc">PMC4317671</ArticleId><ArticleId IdType="pubmed">26038760</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutsuna S, Kato Y, Moi ML, Kotaki A, Ota M, Shinohara K, et al. . Autochthonous dengue fever, Tokyo, Japan, 2014. Emerg Infect Dis. (2015) 21:517&#x2013;20. 10.3201/eid2103.141662</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2103.141662</ArticleId><ArticleId IdType="pmc">PMC4344289</ArticleId><ArticleId IdType="pubmed">25695200</ArticleId></ArticleIdList></Reference><Reference><Citation>Jupp P, McIntosh B. Chikungunya virus disease. In: Monath T. editor. The Arboviruses: Epidemiology and Ecology. Boca Raton Florida: CRC Press; (1988) p. 137&#x2013;57.</Citation></Reference><Reference><Citation>Powers AM, Brault AC, Tesh RB, Weaver SC. Re-emergence of chikungunya and o'nyong-nyong viruses: evidence for distinct geographical lineages and distant evolutionary relationships. J Gen Virol. (2000) 81:471&#x2013;9. 10.1099/0022-1317-81-2-471</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-81-2-471</ArticleId><ArticleId IdType="pubmed">10644846</ArticleId></ArticleIdList></Reference><Reference><Citation>Karabatsos N. International Catalogue of Arthropod-Borne Viruses. 3rd ed. San Antonio, TX: Am Soc Trop Med Hyg; (1985). p. 3.</Citation></Reference><Reference><Citation>Burt FJ, Chen W, Miner JJ, Lenschow DJ, Merits A, Schnettler E, et al. . Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen. Lancet Infect Dis. (2017) 17:e107&#x2013;17. 10.1016/S1473-3099(16)30385-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(16)30385-1</ArticleId><ArticleId IdType="pubmed">28159534</ArticleId></ArticleIdList></Reference><Reference><Citation>Kariuki Njenga M, Nderitu L, Ledermann JP, Ndirangu A, Logue CH, Kelly CHL, et al. . Tracking epidemic Chikungunya virus into the Indian Ocean from East Africa. J Gen Virol. (2008) 89:2754&#x2013;60. 10.1099/vir.0.2008/005413-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.2008/005413-0</ArticleId><ArticleId IdType="pmc">PMC3347796</ArticleId><ArticleId IdType="pubmed">18931072</ArticleId></ArticleIdList></Reference><Reference><Citation>Angelini R, Finarelli AC, Angelini P, Petropulacos K, Macini P, Fiorentini C, et al. . An outbreak of chikungunya fever in the province of Ravenna, Italy. Euro Surveill. (2007) 12:E070906.1. 10.2807/esw.12.36.03260-en</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/esw.12.36.03260-en</ArticleId><ArticleId IdType="pubmed">17900424</ArticleId></ArticleIdList></Reference><Reference><Citation>Staples JE, Fischer M. Chikungunya virus in the Americas&#x2014;what a vector-borne pathogen can do. N Engl J Med. (2014) 371:887&#x2013;9. 10.1056/NEJMp1407698</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp1407698</ArticleId><ArticleId IdType="pmc">PMC4624217</ArticleId><ArticleId IdType="pubmed">25184860</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer M, Staples JE. Notes from the field: Chikungunya virus spreads in the Americas-Caribbean and South America, 2013&#x2013;2014. MMWR Morb Mortal Wkly Rep. (2014) 63:500&#x2013;1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5779358</ArticleId><ArticleId IdType="pubmed">24898168</ArticleId></ArticleIdList></Reference><Reference><Citation>Ergonul O. Crimean-Congo hemorrhagic fever virus: new outbreaks, new discoveries. Curr Opin Virol. (2012) 2:215&#x2013;20. 10.1016/j.coviro.2012.03.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2012.03.001</ArticleId><ArticleId IdType="pubmed">22482717</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Wal BW, Joubert JR, van Eeden PJ, King JB. A nosocomial outbreak of Crimean-Congo haemorrhagic fever at Tygerberg Hospital. Part IV. Preventive and prophylactic measures. S Afr Med J. (1985) 68:729&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">2414853</ArticleId></ArticleIdList></Reference><Reference><Citation>Mardani M, Rahnavardi M, Rajaeinejad M, Naini KH, Chinikar S, Pourmalek F. Crimean-Congo hemorrhagic fever among health care workers in Iran: a seroprevalence study in two endemic regions. Am J Trop Med Hyg. (2007) 76:443. 10.4269/ajtmh.2007.76.443</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.2007.76.443</ArticleId><ArticleId IdType="pubmed">17360865</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra AC, Mehta M, Mourya DT, Gandhi S. Crimean-Congo haemorrhagic fever in India. Lancet. (2011) 378:372. 10.1016/S0140-6736(11)60680-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(11)60680-6</ArticleId><ArticleId IdType="pubmed">21784269</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xfc;t&#xfc;nc&#xfc; EE, Gurbuz Y, Ozturk B, Kuscu F, Sencan I. Crimean Congo haemorrhagic fever, precautions and ribavirin prophylaxis: a case report. Scand J Infect Dis. (2009) 41:378&#x2013;80. 10.1080/00365540902882434</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00365540902882434</ArticleId><ArticleId IdType="pubmed">19343611</ArticleId></ArticleIdList></Reference><Reference><Citation>Portillo A, Palomar AM, Santibanez P, Oteo JA. Epidemiological aspects of crimean-congo hemorrhagic fever in Western Europe: what about the future? Microorganisms. (2021) 9:649. 10.3390/microorganisms9030649</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms9030649</ArticleId><ArticleId IdType="pmc">PMC8003855</ArticleId><ArticleId IdType="pubmed">33801015</ArticleId></ArticleIdList></Reference><Reference><Citation>Negredo A, de la Calle-Prieto F, Palencia-Herrej&#xf3;n E, Mora-Rillo M, Astray-Mochales J, S&#xe1;nchez-Seco MP, et al. . Autochthonous Crimean&#x2013;Congo hemorrhagic fever in Spain. N Engl J Med. (2017) 377:154&#x2013;61. 10.1056/NEJMoa1615162</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1615162</ArticleId><ArticleId IdType="pubmed">28700843</ArticleId></ArticleIdList></Reference><Reference><Citation>Bente DA, Forrester NL, Watts DM, McAuley AJ, Whitehouse CA, Bray M. Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity. Antiviral Res. (2013) 100:159&#x2013;89. 10.1016/j.antiviral.2013.07.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2013.07.006</ArticleId><ArticleId IdType="pubmed">23906741</ArticleId></ArticleIdList></Reference><Reference><Citation>Ince Y, Yasa C, Metin M, Sonmez M, Meram E, Benkli B, et al. . Crimean-Congo hemorrhagic fever infections reported by ProMED. Int J Infect Dis. (2014) 26:44&#x2013;6. 10.1016/j.ijid.2014.04.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2014.04.005</ArticleId><ArticleId IdType="pubmed">24947424</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn PC. The molecular basis of virulence of the encephalitogenic flaviviruses. J Gen Virol. (1997) 78:2711&#x2013;22. 10.1099/0022-1317-78-11-2711</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-78-11-2711</ArticleId><ArticleId IdType="pubmed">9367356</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffiths MJ, Turtle L, Solomon T. Chapter 26-Japanese encephalitis virus infection. Handb Clin Neurol. (2014) 123:561&#x2013;76. 10.1016/B978-0-444-53488-0.00026-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-444-53488-0.00026-2</ArticleId><ArticleId IdType="pubmed">25015504</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Luo H, Rehman MU, Nabi F, Li K, Lan Y, et al. . Evidence of JEV in Culex tritaeniorhynchus and pigs from high altitude regions of Tibet, China. J Vector Borne Dis. (2017) 54:69&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">28352048</ArticleId></ArticleIdList></Reference><Reference><Citation>Steere AC. Lyme disease. N Engl J Med. (2001) 345:115&#x2013;25. 10.1056/NEJM200107123450207</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200107123450207</ArticleId><ArticleId IdType="pubmed">11450660</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC . Centers for Disease Control and Prevention. 2019. Lyme Disease Data Tables: Historical Data. (2019). Available online at: www.cdc.gov/lyme/stats/tables.html (accessed January 2021).</Citation></Reference><Reference><Citation>Hofhuis A, Harms M, van den Wijngaard C, Sprong H, van Pelt W. Continuing increase of tick bites and Lyme disease between 1994 and 2009. Ticks Tick Borne Dis. (2015) 6:69&#x2013;74. 10.1016/j.ttbdis.2014.09.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ttbdis.2014.09.006</ArticleId><ArticleId IdType="pubmed">25448421</ArticleId></ArticleIdList></Reference><Reference><Citation>Steere AC, Coburn J, Glickstein L. The emergence of Lyme disease. J Clin Invest. (2004) 113:1093&#x2013;101. 10.1172/JCI21681</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI21681</ArticleId><ArticleId IdType="pmc">PMC385417</ArticleId><ArticleId IdType="pubmed">15085185</ArticleId></ArticleIdList></Reference><Reference><Citation>Beard CB, Eisen RJ, Barker CM, Garofalo JF, Hahn MM, Hayden AJ, et al. . Chapter 5: vector-borne diseases. In: The Impacts of Climate Change on Human Health in the United States: A Scientific Assessment. Washington, DC: U.S. Global Change Research Program;  (2016). Available online at: https://health2016.globalchange.gov</Citation></Reference><Reference><Citation>Daubney R, Hudson JR, Garnham PC. Enzoonotic hepatitis or rift valley fever. An undescribed virus disease of sheep, cattle and man from east africa. J Pathol Bacteriol. (1931) 34:545&#x2013;79. 10.1002/path.1700340418</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.1700340418</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolin AI, Berrang-Ford L, Kulkarni MA. The risk of Rift Valley fever virus introduction and establishment in the United States and European Union. Emerg Microbes Infect. (2013) 2:e81. 10.1038/emi.2013.81</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emi.2013.81</ArticleId><ArticleId IdType="pmc">PMC3880870</ArticleId><ArticleId IdType="pubmed">26038446</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanyingi MO, Munyua P, Kiama SG, Muchemi GM, Thumbi SM, Bitek AO, et al. . A systematic review of Rift Valley Fever epidemiology 1931-2014. Infect Ecol Epidemiol. (2015) 5:28024. 10.3402/iee.v5.28024</Citation><ArticleIdList><ArticleId IdType="doi">10.3402/iee.v5.28024</ArticleId><ArticleId IdType="pmc">PMC4522434</ArticleId><ArticleId IdType="pubmed">26234531</ArticleId></ArticleIdList></Reference><Reference><Citation>Calasans TAS, Souza GTR, Melo CM, Madi RR, Jeraldo VLS. Socioenvironmental factors associated with Schistosoma mansoni infection and intermediate hosts in an urban area of northeastern Brazil. PLoS ONE. (2018) 13:e0195519. 10.1371/journal.pone.0195519</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0195519</ArticleId><ArticleId IdType="pmc">PMC5931446</ArticleId><ArticleId IdType="pubmed">29718924</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotez PJ. Southern Europe's coming plagues: vector-borne neglected tropical diseases. PLoS Negl Trop Dis. (2016) 10:e0004243. 10.1371/journal.pntd.0004243</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0004243</ArticleId><ArticleId IdType="pmc">PMC4928793</ArticleId><ArticleId IdType="pubmed">27362640</ArticleId></ArticleIdList></Reference><Reference><Citation>Mwakitalu ME, Malecela MN, Mosha FW, Simonsen PE. Urban schistosomiasis and soil transmitted helminthiases in young school children in Dar es Salaam and Tanga, Tanzania, after a decade of anthelminthic intervention. Acta Trop. (2014) 133:35&#x2013;41. 10.1016/j.actatropica.2014.01.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.actatropica.2014.01.012</ArticleId><ArticleId IdType="pubmed">24495630</ArticleId></ArticleIdList></Reference><Reference><Citation>Klohe K, Koudou BG, Fenwick A, Fleming F, Garba A, Gouvras A, et al. . A systematic literature review of schistosomiasis in urban and peri-urban settings. PLoS Negl Trop Dis. (2021) 15:e0008995. 10.1371/journal.pntd.0008995</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0008995</ArticleId><ArticleId IdType="pmc">PMC7906408</ArticleId><ArticleId IdType="pubmed">33630833</ArticleId></ArticleIdList></Reference><Reference><Citation>Smithburn K, Hughes T, Burke A. A neurotropic virus isolated from the blood of a native of Uganda. Am J Trop Med. (1940) 20:471&#x2013;92. 10.4269/ajtmh.1940.s1-20.471</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.1940.s1-20.471</ArticleId></ArticleIdList></Reference><Reference><Citation>Murgue B, Murri S, Triki H, Deubel V, Zeller HG. West Nile in the Mediterranean basin: 1950-2000. Ann N Y Acad Sci. (2001) 951:117&#x2013;26. 10.1111/j.1749-6632.2001.tb02690.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2001.tb02690.x</ArticleId><ArticleId IdType="pubmed">11797769</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronca SE, Murray KO, Nolan MS. Cumulative incidence of West Nile virus infection, continental United States, 1999&#x2013;2016. Emerg Infect Dis. (2019) 25:325. 10.3201/eid2502.180765</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2502.180765</ArticleId><ArticleId IdType="pmc">PMC6346444</ArticleId><ArticleId IdType="pubmed">30666940</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC . 8 Zoonotic Diseases Shared Between Animals and People of Most Concern in the U.S. Available online at: www.cdc.gov/media/releases/2019/s0506-zoonotic-diseases-shared.html (accessed May 6, 2019).</Citation></Reference><Reference><Citation>Mackenzie JS, Gubler DJ, Petersen LR. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med. (2004)10:S98&#x2013;109. 10.1038/nm1144</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1144</ArticleId><ArticleId IdType="pubmed">15577938</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter HR. Yellow Fever: An Epidemiological and Historical Study of Its Place of Origin. Baltimore, MD: Williams &amp; Wilkins; (1931).</Citation></Reference><Reference><Citation>Gershman MD, Staples JE. Chapter 3: Yellow Book. In: Infectious Diseases Related to Travel: Yellow Fever (2014). Available online at: http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/yellow-fever (accessed March 12, 2021).</Citation></Reference><Reference><Citation>WHO . Emergencies: Yellow Fever Situation Report. (2017). Available online at: http://www.who.int/emergencies/yellow-fever/situation-reports/2-june-2016/en/ (accessed April, 2021).</Citation></Reference><Reference><Citation>Chen LH, Wilson ME. Yellow fever control: current epidemiology and vaccination strategies. Trop Dis Travel Med Vaccines. (2020) 6:1. 10.1186/s40794-020-0101-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40794-020-0101-0</ArticleId><ArticleId IdType="pmc">PMC6954598</ArticleId><ArticleId IdType="pubmed">31938550</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . Vaccines and vaccination against yellow fever. WHO position paper &#x2013; June 2013. Wkly Epidemiol Rec. (2013) 88:269&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">23909008</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson DI. Zika virus infection in man. Trans R Soc Trop Med Hyg. (1964) 58:335&#x2013;8. 10.1016/0035-9203(64)90201-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0035-9203(64)90201-9</ArticleId><ArticleId IdType="pubmed">14175744</ArticleId></ArticleIdList></Reference><Reference><Citation>Belluck P, Alvarez L. Zika Cases in Florida Were Likely Spread by Local Mosquitoes, CDC Says. The New York Times; (2016).</Citation></Reference><Reference><Citation>Duffy MR, Chen TH, Hancock WT, Powers AM, Kool JL, Lanciotti RS, et al. . Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med. (2009) 360:2536&#x2013;43. 10.1056/NEJMoa0805715</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0805715</ArticleId><ArticleId IdType="pubmed">19516034</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth A, Mercier A, Lepers C, Hoy D, Duituturaga S, Benyon E, et al. . Concurrent outbreaks of dengue, chikungunya and Zika virus infections - an unprecedented epidemic wave of mosquito-borne viruses in the Pacific 2012-2014. Euro Surveill. (2014) 19:1&#x2013;8. 10.2807/1560-7917.ES2014.19.41.20929</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES2014.19.41.20929</ArticleId><ArticleId IdType="pubmed">25345518</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupont-Rouzeyrol M, O'Connor O, Calvez E, Daures M, John M, Grangeon JP, et al. . Co-infection with Zika and dengue viruses in 2 patients, New Caledonia, 2014. Emerg Infect Dis. (2015) 21:381&#x2013;2. 10.3201/eid2102.141553</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2102.141553</ArticleId><ArticleId IdType="pmc">PMC4313662</ArticleId><ArticleId IdType="pubmed">25625687</ArticleId></ArticleIdList></Reference><Reference><Citation>Fauci AS, Morens DM. Zika virus in the Americas yet another arbovirus threat. N Engl J Med. (2016) 374:601&#x2013;4. 10.1056/NEJMp1600297</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp1600297</ArticleId><ArticleId IdType="pubmed">26761185</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones KE, Patel NG, Levy MA, Storeygard A, Balk D, Gittleman JL, et al. . Global trends in emerging infectious diseases. Nature. (2008) 451:990&#x2013;3. 10.1038/nature06536</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature06536</ArticleId><ArticleId IdType="pmc">PMC5960580</ArticleId><ArticleId IdType="pubmed">18288193</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver SC, Reisen WK. Present and future arboviral threats. Antiviral Res. (2010) 85:328&#x2013;45. 10.1016/j.antiviral.2009.10.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2009.10.008</ArticleId><ArticleId IdType="pmc">PMC2815176</ArticleId><ArticleId IdType="pubmed">19857523</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan SJ, Carlson CJ, Mordecai EA, Johnson LR. Global expansion and redistribution of aedes-borne virus transmission risk with climate change. PloS Negl Trop Dis. (2019) 13:e0007213. 10.1371/journal.pntd.0007213</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0007213</ArticleId><ArticleId IdType="pmc">PMC6438455</ArticleId><ArticleId IdType="pubmed">30921321</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . Vector-Borne Diseases. (2020). Available online at: www.who.int/news-room/fact-sheets/detail/vector-borne-diseases (accessed May 2021).</Citation></Reference><Reference><Citation>Rabaan AA, Al-Ahmed SH, Sah R, Al-Tawfiq JA, Haque S, Harapan H, et al. . Genomic epidemiology and recent update on nucleic acid-based diagnostics for COVID-19. Curr Trop Med Rep. (2020) 7:113&#x2013;9. 10.1007/s40475-020-00212-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40475-020-00212-3</ArticleId><ArticleId IdType="pmc">PMC7513458</ArticleId><ArticleId IdType="pubmed">32989413</ArticleId></ArticleIdList></Reference><Reference><Citation>Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. . Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. (2012) 380:2095&#x2013;128. 10.1016/S0140-6736(12)61728-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(12)61728-0</ArticleId><ArticleId IdType="pmc">PMC10790329</ArticleId><ArticleId IdType="pubmed">23245604</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranson H, N'guessan R, Lines J, Moiroux N, Nkuni Z, Corbel V. Pyrethroid resistance in African anopheline mosquitoes: what are the implications for malaria control? Trends Parasitol. (2011) 27:91&#x2013;8. 10.1016/j.pt.2010.08.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pt.2010.08.004</ArticleId><ArticleId IdType="pubmed">20843745</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson AL, Courtenay O, Kelly-Hope LA, Scott TW, Takken W, Torr SJ, et al. . The importance of vector control for the control and elimination of vector-borne diseases. PLoS Negl Trop Dis. (2020) 14:e0007831. 10.1371/journal.pntd.0007831</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0007831</ArticleId><ArticleId IdType="pmc">PMC6964823</ArticleId><ArticleId IdType="pubmed">31945061</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33516423</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-299X</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Primary care</Title><ISOAbbreviation>Prim Care</ISOAbbreviation></Journal><ArticleTitle>Common Infectious Diseases.</ArticleTitle><Pagination><StartPage>45</StartPage><EndPage>55</EndPage><MedlinePgn>45-55</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pop.2020.11.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0095-4543(20)30090-7</ELocationID><Abstract><AbstractText>The initial assessment of immigrant and refugee patients, including which health concerns to address and which infectious diseases may benefit from early screening, may present challenges to clinicians. Evidence-based research suggests certain infectious diseases should be screened for and treated in refugees. Overseas refugee preemptive treatment programs have reduced the burden of some diseases but have not removed the value of in-country screening programs. This article provides discussion of a series of common tropical and infectious diseases providing refugee and geographic contexts and links to international resources that have been developed to improve the care of newly arriving immigrants and refugees.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pottie</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Family Medicine, School of Epidemiology Public Health and Preventive Medicine, University of Ottawa, Ottawa, Ontario, Canada. Electronic address: kpottie@uottawa.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Girard</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>University of Ottawa, 600 Peter Morand Crescent #201, Ottawa, ON K1G 5Z3, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Prim Care</MedlineTA><NlmUniqueID>0430463</NlmUniqueID><ISSNLinking>0095-4543</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003141" MajorTopicYN="N">Communicable Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000208" MajorTopicYN="Y">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054242" MajorTopicYN="Y">Emigrants and Immigrants</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008403" MajorTopicYN="N">Mass Screening</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012036" MajorTopicYN="Y">Refugees</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HIV</Keyword><Keyword MajorTopicYN="N">Hepatitis B</Keyword><Keyword MajorTopicYN="N">Hepatitis C</Keyword><Keyword MajorTopicYN="N">Immigrants</Keyword><Keyword MajorTopicYN="N">Infectious diseases</Keyword><Keyword MajorTopicYN="N">Intestinal parasites</Keyword><Keyword MajorTopicYN="N">Refugees</Keyword><Keyword MajorTopicYN="N">Tuberculosis</Keyword></KeywordList><CoiStatement>Disclosure The authors have nothing to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>31</Day><Hour>20</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33516423</ArticleId><ArticleId IdType="doi">10.1016/j.pop.2020.11.002</ArticleId><ArticleId IdType="pii">S0095-4543(20)30090-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35077138</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2161-5063</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month><Day>18</Day></PubDate></JournalIssue><Title>ACS synthetic biology</Title><ISOAbbreviation>ACS Synth Biol</ISOAbbreviation></Journal><ArticleTitle>Combating Infectious Diseases with Synthetic Biology.</ArticleTitle><Pagination><StartPage>528</StartPage><EndPage>537</EndPage><MedlinePgn>528-537</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acssynbio.1c00576</ELocationID><Abstract><AbstractText>Over the past decades, there have been numerous outbreaks, including parasitic, fungal, bacterial, and viral infections, worldwide. The rate at which infectious diseases are emerging is disproportionate to the rate of development for new strategies that could combat them. Therefore, there is an increasing demand to develop novel, specific, sensitive, and effective methods for infectious disease diagnosis and treatment. Designed synthetic systems and devices are becoming powerful tools to treat human diseases. The advancement in synthetic biology offers efficient, accurate, and cost-effective platforms for detecting and preventing infectious diseases. Herein we focus on the latest state of living theranostics and its implications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Anooshay</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>UNAM - National Nanotechnology Research Center, Institute of Materials Science and Nanotechnology Bilkent University, 06800 Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostaku</LastName><ForeName>Julian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>UNAM - National Nanotechnology Research Center, Institute of Materials Science and Nanotechnology Bilkent University, 06800 Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aras</LastName><ForeName>Ebru</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>UNAM - National Nanotechnology Research Center, Institute of Materials Science and Nanotechnology Bilkent University, 06800 Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Safak Seker</LastName><ForeName>Urartu Ozgur</ForeName><Initials>UO</Initials><Identifier Source="ORCID">0000-0002-5272-1876</Identifier><AffiliationInfo><Affiliation>UNAM - National Nanotechnology Research Center, Institute of Materials Science and Nanotechnology Bilkent University, 06800 Ankara, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ACS Synth Biol</MedlineTA><NlmUniqueID>101575075</NlmUniqueID><ISSNLinking>2161-5063</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018407" MajorTopicYN="N">Bacterial Physiological Phenomena</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001435" MajorTopicYN="N">Bacteriophages</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003140" MajorTopicYN="N">Communicable Disease Control</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057285" MajorTopicYN="N">Precision Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058615" MajorTopicYN="Y">Synthetic Biology</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">diagnostics</Keyword><Keyword MajorTopicYN="N">engineered phage and bacteria</Keyword><Keyword MajorTopicYN="N">infectious diseases</Keyword><Keyword MajorTopicYN="N">synthetic biology</Keyword><Keyword MajorTopicYN="N">therapeutics</Keyword></KeywordList><CoiStatement>The authors
declare no competing financial interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>25</Day><Hour>17</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35077138</ArticleId><ArticleId IdType="pmc">PMC8895449</ArticleId><ArticleId IdType="doi">10.1021/acssynbio.1c00576</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Coltart C. E.; Lindsey B.; Ghinai I.; Johnson A. M.; Heymann D. L. The Ebola outbreak, 2013&#x2013;2016: old lessons for new epidemics. Phil. Trans. R. Soc. B 2017, 372 (1721), 20160297.10.1098/rstb.2016.0297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rstb.2016.0297</ArticleId><ArticleId IdType="pmc">PMC5394636</ArticleId><ArticleId IdType="pubmed">28396469</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson R. M.; Fraser C.; Ghani A. C.; Donnelly C. A.; Riley S.; Ferguson N. M.; Leung G. M.; Lam T. H.; Hedley A. J. Epidemiology, transmission dynamics and control of SARS: the 2002&#x2013;2003 epidemic. Philos. Trans R Soc. Lond B Biol. Sci. 2004, 359 (1447), 1091&#x2013;105. 10.1098/rstb.2004.1490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rstb.2004.1490</ArticleId><ArticleId IdType="pmc">PMC1693389</ArticleId><ArticleId IdType="pubmed">15306395</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutchings M. I.; Truman A. W.; Wilkinson B. Antibiotics: past, present and future. Curr. Opin Microbiol 2019, 51, 72&#x2013;80. 10.1016/j.mib.2019.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mib.2019.10.008</ArticleId><ArticleId IdType="pubmed">31733401</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C.; Liu M.; Wang Z.; Li S.; Deng Y.; He N. Point-of-care diagnostics for infectious diseases: From methods to devices. Nano Today 2021, 37, 101092.10.1016/j.nantod.2021.101092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nantod.2021.101092</ArticleId><ArticleId IdType="pmc">PMC7864790</ArticleId><ArticleId IdType="pubmed">33584847</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng F.; Ellis T. The second decade of synthetic biology: 2010&#x2013;2020. Nat. Commun. 2020, 11 (1), 5174.10.1038/s41467-020-19092-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19092-2</ArticleId><ArticleId IdType="pmc">PMC7560693</ArticleId><ArticleId IdType="pubmed">33057059</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks S. M.; Alper H. S. Applications, challenges, and needs for employing synthetic biology beyond the lab. Nat. Commun. 2021, 12 (1), 1390.10.1038/s41467-021-21740-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21740-0</ArticleId><ArticleId IdType="pmc">PMC7925609</ArticleId><ArticleId IdType="pubmed">33654085</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert J. A.; Blaser M. J.; Caporaso J. G.; Jansson J. K.; Lynch S. V.; Knight R. Current understanding of the human microbiome. Nat. Med. 2018, 24 (4), 392&#x2013;400. 10.1038/nm.4517.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4517</ArticleId><ArticleId IdType="pmc">PMC7043356</ArticleId><ArticleId IdType="pubmed">29634682</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain T.; Sharma P.; Are A. C.; Vickers S. M.; Dudeja V. New Insights Into the Cancer-Microbiome-Immune Axis: Decrypting a Decade of Discoveries. Front Immunol 2021, 12, 622064.10.3389/fimmu.2021.622064.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.622064</ArticleId><ArticleId IdType="pmc">PMC7940198</ArticleId><ArticleId IdType="pubmed">33708214</ArticleId></ArticleIdList></Reference><Reference><Citation>Manor O.; Dai C. L.; Kornilov S. A.; Smith B.; Price N. D.; Lovejoy J. C.; Gibbons S. M.; Magis A. T. Health and disease markers correlate with gut microbiome composition across thousands of people. Nat. Commun. 2020, 11 (1), 5206.10.1038/s41467-020-18871-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18871-1</ArticleId><ArticleId IdType="pmc">PMC7562722</ArticleId><ArticleId IdType="pubmed">33060586</ArticleId></ArticleIdList></Reference><Reference><Citation>Chappell T. C.; Nair N. U. Engineered lactobacilli display anti-biofilm and growth suppressing activities against Pseudomonas aeruginosa. NPJ Biofilms Microbiomes 2020, 6 (1), 48.10.1038/s41522-020-00156-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41522-020-00156-6</ArticleId><ArticleId IdType="pmc">PMC7599214</ArticleId><ArticleId IdType="pubmed">33127888</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrido V.; Pinero-Lambea C.; Rodriguez-Arce I.; Paetzold B.; Ferrar T.; Weber M.; Garcia-Ramallo E.; Gallo C.; Collantes M.; Penuelas I.; Serrano L.; Grillo M. J.; Lluch-Senar M. Engineering a genome-reduced bacterium to eliminate Staphylococcus aureus biofilms in vivo. Mol. Syst. Biol. 2021, 17 (10), e1014510.15252/msb.202010145.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/msb.202010145</ArticleId><ArticleId IdType="pmc">PMC8493563</ArticleId><ArticleId IdType="pubmed">34612607</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer J. D.; Piattelli E.; McCormick B. A.; Silby M. W.; Brigham C. J.; Bucci V. Engineered Probiotic for the Inhibition of Salmonella via Tetrathionate-Induced Production of Microcin H47. ACS Infect Dis 2018, 4 (1), 39&#x2013;45. 10.1021/acsinfecdis.7b00114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.7b00114</ArticleId><ArticleId IdType="pmc">PMC5766358</ArticleId><ArticleId IdType="pubmed">28918634</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedrolli D. B.; Ribeiro N. V.; Squizato P. N.; de Jesus V. N.; Cozetto D. A.; Tuma R. B.; Gracindo A.; Cesar M. B.; Freire P. J.C.; da Costa A. F.M.; Lins M. R.C.R.; Correa G. G.; Cerri M. O. Engineering Microbial Living Therapeutics: The Synthetic Biology Toolbox. Trends Biotechnol. 2019, 37 (1), 100&#x2013;115. 10.1016/j.tibtech.2018.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibtech.2018.09.005</ArticleId><ArticleId IdType="pubmed">30318171</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahan R. E.; Kirpat B. M.; Saltepe B.; Seker U. O. S. A Self-Actuated Cellular Protein Delivery Machine. ACS Synth. Biol. 2019, 8 (4), 686&#x2013;696. 10.1021/acssynbio.9b00062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acssynbio.9b00062</ArticleId><ArticleId IdType="pubmed">30811932</ArticleId></ArticleIdList></Reference><Reference><Citation>Barger N.; Litovco P.; Li X.; Habib M.; Daniel R. Synthetic metabolic computation in a bioluminescence-sensing system. Nucleic Acids Res. 2019, 47 (19), 10464&#x2013;10474. 10.1093/nar/gkz807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz807</ArticleId><ArticleId IdType="pmc">PMC6821183</ArticleId><ArticleId IdType="pubmed">31544939</ArticleId></ArticleIdList></Reference><Reference><Citation>Landry B. P.; Palanki R.; Dyulgyarov N.; Hartsough L. A.; Tabor J. J. Phosphatase activity tunes two-component system sensor detection threshold. Nat. Commun. 2018, 9 (1), 1433.10.1038/s41467-018-03929-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-03929-y</ArticleId><ArticleId IdType="pmc">PMC5897336</ArticleId><ArticleId IdType="pubmed">29650958</ArticleId></ArticleIdList></Reference><Reference><Citation>Litovco P.; Barger N.; Li X.; Daniel R. Topologies of synthetic gene circuit for optimal fold change activation. Nucleic Acids Res. 2021, 49 (9), 5393&#x2013;5406. 10.1093/nar/gkab253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkab253</ArticleId><ArticleId IdType="pmc">PMC8136830</ArticleId><ArticleId IdType="pubmed">34009384</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien T.; Harimoto T.; Kepecs B.; Gray K.; Coker C.; Hou N.; Pu K.; Azad T.; Nolasco A.; Pavlicova M.; Danino T. Enhancing the tropism of bacteria via genetically programmed biosensors. Nat. Biomed Eng. 2022, 6, 94.10.1038/s41551-021-00772-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41551-021-00772-3</ArticleId><ArticleId IdType="pmc">PMC8956018</ArticleId><ArticleId IdType="pubmed">34326488</ArticleId></ArticleIdList></Reference><Reference><Citation>Din M. O.; Danino T.; Prindle A.; Skalak M.; Selimkhanov J.; Allen K.; Julio E.; Atolia E.; Tsimring L. S.; Bhatia S. N.; Hasty J. Synchronized cycles of bacterial lysis for in vivo delivery. Nature 2016, 536 (7614), 81&#x2013;85. 10.1038/nature18930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature18930</ArticleId><ArticleId IdType="pmc">PMC5048415</ArticleId><ArticleId IdType="pubmed">27437587</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurbatri C. R.; Lia I.; Vincent R.; Coker C.; Castro S.; Treuting P. M.; Hinchliffe T. E.; Arpaia N.; Danino T. Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies. Sci. Transl. Med. 2020, 10.1126/scitranslmed.aax0876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aax0876</ArticleId><ArticleId IdType="pmc">PMC7685004</ArticleId><ArticleId IdType="pubmed">32051224</ArticleId></ArticleIdList></Reference><Reference><Citation>Harimoto T.; Singer Z. S.; Velazquez O. S.; Zhang J.; Castro S.; Hinchliffe T. E.; Mather W.; Danino T. Rapid screening of engineered microbial therapies in a 3D multicellular model. Proc. Natl. Acad. Sci. U. S. A. 2019, 116 (18), 9002&#x2013;9007. 10.1073/pnas.1820824116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1820824116</ArticleId><ArticleId IdType="pmc">PMC6500119</ArticleId><ArticleId IdType="pubmed">30996123</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao N.; Cubillos-Ruiz A.; Cameron D. E.; Collins J. J. Probiotic strains detect and suppress cholera in mice. Sci. Transl. Med. 2018, 10.1126/scitranslmed.aao2586.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aao2586</ArticleId><ArticleId IdType="pmc">PMC7821980</ArticleId><ArticleId IdType="pubmed">29899022</ArticleId></ArticleIdList></Reference><Reference><Citation>Diarrhoeal Disease. World Health
Organization. https://www.who.int/news-room/fact-sheets/detail/diarrhoeal-disease.</Citation></Reference><Reference><Citation>Mukherjee S.; Bassler B. L. Bacterial quorum sensing in complex and dynamically changing environments. Nat. Rev. Microbiol 2019, 17 (6), 371&#x2013;382. 10.1038/s41579-019-0186-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-019-0186-5</ArticleId><ArticleId IdType="pmc">PMC6615036</ArticleId><ArticleId IdType="pubmed">30944413</ArticleId></ArticleIdList></Reference><Reference><Citation>Holowko M. B.; Wang H.; Jayaraman P.; Poh C. L. Biosensing Vibrio cholerae with Genetically Engineered Escherichia coli. ACS Synth. Biol. 2016, 5 (11), 1275&#x2013;1283. 10.1021/acssynbio.6b00079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acssynbio.6b00079</ArticleId><ArticleId IdType="pubmed">27529184</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayaraman P.; Holowko M. B.; Yeoh J. W.; Lim S.; Poh C. L. Repurposing a Two-Component System-Based Biosensor for the Killing of Vibrio cholerae. ACS Synth. Biol. 2017, 6 (7), 1403&#x2013;1415. 10.1021/acssynbio.7b00058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acssynbio.7b00058</ArticleId><ArticleId IdType="pubmed">28441472</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassetti M.; Vena A.; Croxatto A.; Righi E.; Guery B. How to manage Pseudomonas aeruginosa infections. Drugs Context 2018, 7, 212527.10.7573/dic.212527.</Citation><ArticleIdList><ArticleId IdType="doi">10.7573/dic.212527</ArticleId><ArticleId IdType="pmc">PMC5978525</ArticleId><ArticleId IdType="pubmed">29872449</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan S.; Wu G. Can Biofilm Be Reversed Through Quorum Sensing in Pseudomonas aeruginosa?. Front. Microbiol. 2019, 10, 1582.10.3389/fmicb.2019.01582.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2019.01582</ArticleId><ArticleId IdType="pmc">PMC6664025</ArticleId><ArticleId IdType="pubmed">31396166</ArticleId></ArticleIdList></Reference><Reference><Citation>Saeidi N.; Wong C. K.; Lo T. M.; Nguyen H. X.; Ling H.; Leong S. S.; Poh C. L.; Chang M. W. Engineering microbes to sense and eradicate Pseudomonas aeruginosa, a human pathogen. Mol. Syst. Biol. 2011, 7, 521.10.1038/msb.2011.55.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/msb.2011.55</ArticleId><ArticleId IdType="pmc">PMC3202794</ArticleId><ArticleId IdType="pubmed">21847113</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang I. Y.; Koh E.; Wong A.; March J. C.; Bentley W. E.; Lee Y. S.; Chang M. W. Engineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models. Nat. Commun. 2017, 8, 15028.10.1038/ncomms15028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms15028</ArticleId><ArticleId IdType="pmc">PMC5394271</ArticleId><ArticleId IdType="pubmed">28398304</ArticleId></ArticleIdList></Reference><Reference><Citation>Grishin A. V.; Konstantinova S. V.; Vasina I. V.; Shestak N. V.; Karyagina A. S.; Lunin V. G. A Simple Protocol for the Determination of Lysostaphin Enzymatic Activity. Antibiotics 2020, 9 (12), 917.10.3390/antibiotics9120917.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics9120917</ArticleId><ArticleId IdType="pmc">PMC7766845</ArticleId><ArticleId IdType="pubmed">33348544</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayakumar J.; Kumar V. A.; Biswas L.; Biswas R. Therapeutic applications of lysostaphin against Staphylococcus aureus. J. Appl. Microbiol. 2021, 131 (3), 1072&#x2013;1082. 10.1111/jam.14985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jam.14985</ArticleId><ArticleId IdType="pubmed">33382154</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin D. M.; Koskella B.; Lin H. C. Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. World J. Gastrointest Pharmacol Ther 2017, 8 (3), 162&#x2013;173. 10.4292/wjgpt.v8.i3.162.</Citation><ArticleIdList><ArticleId IdType="doi">10.4292/wjgpt.v8.i3.162</ArticleId><ArticleId IdType="pmc">PMC5547374</ArticleId><ArticleId IdType="pubmed">28828194</ArticleId></ArticleIdList></Reference><Reference><Citation>Berryhill B. A.; Huseby D. L.; McCall I. C.; Hughes D.; Levin B. R. Evaluating the potential efficacy and limitations of a phage for joint antibiotic and phage therapy of Staphylococcus aureus infections. Proc. Natl. Acad. Sci. U. S. A. 2021, 118 (10), e2008007118.10.1073/pnas.2008007118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2008007118</ArticleId><ArticleId IdType="pmc">PMC7958385</ArticleId><ArticleId IdType="pubmed">33649203</ArticleId></ArticleIdList></Reference><Reference><Citation>Fish R.; Kutter E.; Wheat G.; Blasdel B.; Kutateladze M.; Kuhl S. Compassionate Use of Bacteriophage Therapy for Foot Ulcer Treatment as an Effective Step for Moving Toward Clinical Trials. Methods Mol. Biol. 2018, 1693, 159&#x2013;170. 10.1007/978-1-4939-7395-8_14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-7395-8_14</ArticleId><ArticleId IdType="pubmed">29119440</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M.; Chang R. Y. K.; Lin Y.; Morales S.; Kutter E.; Chan H. K. Phage cocktail powder for Pseudomonas aeruginosa respiratory infections. Int. J. Pharm. 2021, 596, 120200.10.1016/j.ijpharm.2021.120200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2021.120200</ArticleId><ArticleId IdType="pmc">PMC7904610</ArticleId><ArticleId IdType="pubmed">33486032</ArticleId></ArticleIdList></Reference><Reference><Citation>Abedon S. T.; Garcia P.; Mullany P.; Aminov R. Editorial: Phage Therapy: Past, Present and Future. Front. Microbiol. 2017, 8, 981.10.3389/fmicb.2017.00981.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2017.00981</ArticleId><ArticleId IdType="pmc">PMC5471325</ArticleId><ArticleId IdType="pubmed">28663740</ArticleId></ArticleIdList></Reference><Reference><Citation>Principi N.; Silvestri E.; Esposito S. Advantages and Limitations of Bacteriophages for the Treatment of Bacterial Infections. Front. Pharmacol. 2019, 10, 513.10.3389/fphar.2019.00513.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2019.00513</ArticleId><ArticleId IdType="pmc">PMC6517696</ArticleId><ArticleId IdType="pubmed">31139086</ArticleId></ArticleIdList></Reference><Reference><Citation>Ando H.; Lemire S.; Pires D. P.; Lu T. K. Engineering Modular Viral Scaffolds for Targeted Bacterial Population Editing. Cell Syst 2015, 1 (3), 187&#x2013;196. 10.1016/j.cels.2015.08.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cels.2015.08.013</ArticleId><ArticleId IdType="pmc">PMC4785837</ArticleId><ArticleId IdType="pubmed">26973885</ArticleId></ArticleIdList></Reference><Reference><Citation>Yehl K.; Lemire S.; Yang A. C.; Ando H.; Mimee M.; Torres M. T.; de la Fuente-Nunez C.; Lu T. K. Engineering Phage Host-Range and Suppressing Bacterial Resistance through Phage Tail Fiber Mutagenesis. Cell 2019, 179 (2), 459&#x2013;469. 10.1016/j.cell.2019.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.09.015</ArticleId><ArticleId IdType="pmc">PMC6924272</ArticleId><ArticleId IdType="pubmed">31585083</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J. Y.; Moon B. Y.; Park J. W.; Thornton J. A.; Park Y. H.; Seo K. S. Genetic engineering of a temperate phage-based delivery system for CRISPR/Cas9 antimicrobials against Staphylococcus aureus. Sci. Rep 2017, 7, 44929.10.1038/srep44929.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep44929</ArticleId><ArticleId IdType="pmc">PMC5359561</ArticleId><ArticleId IdType="pubmed">28322317</ArticleId></ArticleIdList></Reference><Reference><Citation>Cobb L. H.; Park J.; Swanson E. A.; Beard M. C.; McCabe E. M.; Rourke A. S.; Seo K. S.; Olivier A. K.; Priddy L. B. CRISPR-Cas9 modified bacteriophage for treatment of Staphylococcus aureus induced osteomyelitis and soft tissue infection. PLoS One 2019, 14 (11), e022042110.1371/journal.pone.0220421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0220421</ArticleId><ArticleId IdType="pmc">PMC6874295</ArticleId><ArticleId IdType="pubmed">31756187</ArticleId></ArticleIdList></Reference><Reference><Citation>Landlinger C.; Tisakova L.; Oberbauer V.; Schwebs T.; Muhammad A.; Latka A.; Van Simaey L.; Vaneechoutte M.; Guschin A.; Resch G.; Swidsinski S.; Swidsinski A.; Corsini L. Engineered Phage Endolysin Eliminates Gardnerella Biofilm without Damaging Beneficial Bacteria in Bacterial Vaginosis Ex Vivo. Pathogens 2021, 10 (1), 54.10.3390/pathogens10010054.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens10010054</ArticleId><ArticleId IdType="pmc">PMC7830407</ArticleId><ArticleId IdType="pubmed">33435575</ArticleId></ArticleIdList></Reference><Reference><Citation>Pei R.; Lamas-Samanamud G. R. Inhibition of biofilm formation by T7 bacteriophages producing quorum-quenching enzymes. Appl. Environ. Microbiol. 2014, 80 (17), 5340&#x2013;8. 10.1128/AEM.01434-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.01434-14</ArticleId><ArticleId IdType="pmc">PMC4136088</ArticleId><ArticleId IdType="pubmed">24951790</ArticleId></ArticleIdList></Reference><Reference><Citation>Meile S.; Kilcher S.; Loessner M. J.; Dunne M. Reporter Phage-Based Detection of Bacterial Pathogens: Design Guidelines and Recent Developments. Viruses 2020, 12 (9), 944.10.3390/v12090944.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12090944</ArticleId><ArticleId IdType="pmc">PMC7552063</ArticleId><ArticleId IdType="pubmed">32858938</ArticleId></ArticleIdList></Reference><Reference><Citation>Rondon L.; Urdaniz E.; Latini C.; Payaslian F.; Matteo M.; Sosa E. J.; Do Porto D. F.; Turjanski A. G.; Nemirovsky S.; Hatfull G. F.; Poggi S.; Piuri M. Fluoromycobacteriophages Can Detect Viable Mycobacterium tuberculosis and Determine Phenotypic Rifampicin Resistance in 3&#x2013;5 Days From Sputum Collection. Front. Microbiol. 2018, 9, 1471.10.3389/fmicb.2018.01471.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2018.01471</ArticleId><ArticleId IdType="pmc">PMC6041418</ArticleId><ArticleId IdType="pubmed">30026735</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena H. M.; Gupta V. Phage based Diagnosis of Bacterial Infections. J. Clin. Trials Pathol. Case Stud. 2016, 22&#x2013;25.</Citation></Reference><Reference><Citation>Yang X.; Wisuthiphaet N.; Young G. M.; Nitin N. Rapid detection of Escherichia coli using bacteriophage-induced lysis and image analysis. PLoS One 2020, 15 (6), e023385310.1371/journal.pone.0233853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0233853</ArticleId><ArticleId IdType="pmc">PMC7274428</ArticleId><ArticleId IdType="pubmed">32502212</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng L.; Roose K.; Job E. R.; De Rycke R.; Van Hamme E.; Goncalves A.; Parthoens E.; Cicchelero L.; Sanders N.; Fiers W.; Saelens X. Oral delivery of Escherichia coli persistently infected with M2e-displaying bacteriophages partially protects against influenza A virus. J. Controlled Release 2017, 264, 55&#x2013;65. 10.1016/j.jconrel.2017.08.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2017.08.020</ArticleId><ArticleId IdType="pubmed">28842314</ArticleId></ArticleIdList></Reference><Reference><Citation>Aghebati-Maleki L.; Bakhshinejad B.; Baradaran B.; Motallebnezhad M.; Aghebati-Maleki A.; Nickho H.; Yousefi M.; Majidi J. Phage display as a promising approach for vaccine development. J. Biomed Sci. 2016, 23 (1), 66.10.1186/s12929-016-0285-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-016-0285-9</ArticleId><ArticleId IdType="pmc">PMC5041315</ArticleId><ArticleId IdType="pubmed">27680328</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao P.; Mahalingam M.; Zhu J.; Moayeri M.; Sha J.; Lawrence W. S.; Leppla S. H.; Chopra A. K.; Rao V. B. A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague. mBio 2018, 10.1128/mBio.01926-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.01926-18</ArticleId><ArticleId IdType="pmc">PMC6191538</ArticleId><ArticleId IdType="pubmed">30327445</ArticleId></ArticleIdList></Reference><Reference><Citation>Basu R.; Zhai L.; Contreras A.; Tumban E. Immunization with phage virus-like particles displaying Zika virus potential B-cell epitopes neutralizes Zika virus infection of monkey kidney cells. Vaccine 2018, 36 (10), 1256&#x2013;1264. 10.1016/j.vaccine.2018.01.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.01.056</ArticleId><ArticleId IdType="pubmed">29395533</ArticleId></ArticleIdList></Reference><Reference><Citation>Huh H.; Wong S.; St Jean J.; Slavcev R. Bacteriophage interactions with mammalian tissue: Therapeutic applications. Adv. Drug Delivery Rev. 2019, 145, 4&#x2013;17. 10.1016/j.addr.2019.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2019.01.003</ArticleId><ArticleId IdType="pubmed">30659855</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao Q.; Li X.; Han G.; Zhu Y.; Mao C.; Yang M. Phage-based vaccines. Adv. Drug Deliv Rev. 2019, 145, 40&#x2013;56. 10.1016/j.addr.2018.12.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2018.12.013</ArticleId><ArticleId IdType="pubmed">30594492</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Mora A.; Hernandez-Perez J.; Iqbal H. M. N.; Rito-Palomares M.; Benavides J. Bacteriophage-Based Vaccines: A Potent Approach for Antigen Delivery. Vaccines 2020, 8 (3), 504.10.3390/vaccines8030504.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines8030504</ArticleId><ArticleId IdType="pmc">PMC7565293</ArticleId><ArticleId IdType="pubmed">32899720</ArticleId></ArticleIdList></Reference><Reference><Citation>Richner J. M.; Himansu S.; Dowd K. A.; Butler S. L.; Salazar V.; Fox J. M.; Julander J. G.; Tang W. W.; Shresta S.; Pierson T. C.; Ciaramella G.; Diamond M. S. Modified mRNA Vaccines Protect against Zika Virus Infection. Cell 2017, 168 (6), 1114&#x2013;1125. 10.1016/j.cell.2017.02.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.02.017</ArticleId><ArticleId IdType="pmc">PMC5388441</ArticleId><ArticleId IdType="pubmed">28222903</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Y.; Li J. A novel delivery platform based on Bacteriophage MS2 virus-like particles. Virus Res. 2016, 211, 9&#x2013;16. 10.1016/j.virusres.2015.08.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2015.08.022</ArticleId><ArticleId IdType="pmc">PMC7114531</ArticleId><ArticleId IdType="pubmed">26415756</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Coronavirus Dashboard. World Health
Organization. https://covid19.who.int/.</Citation></Reference><Reference><Citation>Huang Z.; Tian D.; Liu Y.; Lin Z.; Lyon C. J.; Lai W.; Fusco D.; Drouin A.; Yin X.; Hu T.; Ning B. Ultra-sensitive and high-throughput CRISPR-p owered COVID-19 diagnosis. Biosens Bioelectron 2020, 164, 112316.10.1016/j.bios.2020.112316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bios.2020.112316</ArticleId><ArticleId IdType="pmc">PMC7245202</ArticleId><ArticleId IdType="pubmed">32553350</ArticleId></ArticleIdList></Reference><Reference><Citation>Broughton J. P.; Deng X.; Yu G.; Fasching C. L.; Servellita V.; Singh J.; Miao X.; Streithorst J. A.; Granados A.; Sotomayor-Gonzalez A.; Zorn K.; Gopez A.; Hsu E.; Gu W.; Miller S.; Pan C. Y.; Guevara H.; Wadford D. A.; Chen J. S.; Chiu C. Y. CRISPR-Cas12-based detection of SARS-CoV-2. Nat. Biotechnol. 2020, 38 (7), 870&#x2013;874. 10.1038/s41587-020-0513-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-020-0513-4</ArticleId><ArticleId IdType="pmc">PMC9107629</ArticleId><ArticleId IdType="pubmed">32300245</ArticleId></ArticleIdList></Reference><Reference><Citation>Brogan D. J.; Chaverra-Rodriguez D.; Lin C. P.; Smidler A. L.; Yang T.; Alcantara L. M.; Antoshechkin I.; Liu J.; Raban R. R.; Belda-Ferre P.; Knight R.; Komives E. A.; Akbari O. S.. A Sensitive, Rapid, and Portable CasRx-based Diagnostic Assay for SARS-CoV-2. medRxiv, October 20, 2020. 10.1101/2020.10.14.20212795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.10.14.20212795</ArticleId><ArticleId IdType="pmc">PMC8577378</ArticleId><ArticleId IdType="pubmed">34714054</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardee K.; Green A. A.; Takahashi M. K.; Braff D.; Lambert G.; Lee J. W.; Ferrante T.; Ma D.; Donghia N.; Fan M.; Daringer N. M.; Bosch I.; Dudley D. M.; O&#x2019;Connor D. H.; Gehrke L.; Collins J. J. Rapid, Low-Cost Detection of Zika Virus Using Programmable Biomolecular Components. Cell 2016, 165 (5), 1255&#x2013;1266. 10.1016/j.cell.2016.04.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.04.059</ArticleId><ArticleId IdType="pubmed">27160350</ArticleId></ArticleIdList></Reference><Reference><Citation>Koksaldi I. C.; Kose S.; Ahan R. E.; Haciosmanoglu N.; Sahin Kehribar E.; Gungen M. A.; Bastug A.; Dinc B.; Bodur H.; Ozkul A.; Seker U. O. S. SARS-CoV-2 Detection with De Novo-Designed Synthetic Riboregulators. Anal. Chem. 2021, 93 (28), 9719&#x2013;9727. 10.1021/acs.analchem.1c00886.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.analchem.1c00886</ArticleId><ArticleId IdType="pubmed">34192453</ArticleId></ArticleIdList></Reference><Reference><Citation>Slomovic S.; Pardee K.; Collins J. J. Synthetic biology devices for in vitro and in vivo diagnostics. Proc. Natl. Acad. Sci. U. S. A. 2015, 112 (47), 14429&#x2013;35. 10.1073/pnas.1508521112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1508521112</ArticleId><ArticleId IdType="pmc">PMC4664311</ArticleId><ArticleId IdType="pubmed">26598662</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S. Y.; Cheng Q. X.; Wang J. M.; Li X. Y.; Zhang Z. L.; Gao S.; Cao R. B.; Zhao G. P.; Wang J. CRISPR-Cas12a-assisted nucleic acid detection. Cell Discovery 2018, 4, 20.10.1038/s41421-018-0028-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-018-0028-z</ArticleId><ArticleId IdType="pmc">PMC5913299</ArticleId><ArticleId IdType="pubmed">29707234</ArticleId></ArticleIdList></Reference><Reference><Citation>Gootenberg J. S.; Abudayyeh O. O.; Kellner M. J.; Joung J.; Collins J. J.; Zhang F. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. Science 2018, 360 (6387), 439&#x2013;444. 10.1126/science.aaq0179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaq0179</ArticleId><ArticleId IdType="pmc">PMC5961727</ArticleId><ArticleId IdType="pubmed">29449508</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharyya R. P.; Thakku S. G.; Hung D. T. Harnessing CRISPR Effectors for Infectious Disease Diagnostics. ACS Infect Dis 2018, 4 (9), 1278&#x2013;1282. 10.1021/acsinfecdis.8b00170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.8b00170</ArticleId><ArticleId IdType="pubmed">30113801</ArticleId></ArticleIdList></Reference><Reference><Citation>To A. C.; Chu D. H.; Wang A. R.; Li F. C.; Chiu A. W.; Gao D. Y.; Choi C. H. J.; Kong S. K.; Chan T. F.; Chan K. M.; Yip K. Y. A comprehensive web tool for toehold switch design. Bioinformatics 2018, 34 (16), 2862&#x2013;2864. 10.1093/bioinformatics/bty216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bty216</ArticleId><ArticleId IdType="pubmed">29648573</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardee K.; Green A. A.; Ferrante T.; Cameron D. E.; DaleyKeyser A.; Yin P.; Collins J. J. Paper-based synthetic gene networks. Cell 2014, 159 (4), 940&#x2013;54. 10.1016/j.cell.2014.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2014.10.004</ArticleId><ArticleId IdType="pmc">PMC4243060</ArticleId><ArticleId IdType="pubmed">25417167</ArticleId></ArticleIdList></Reference><Reference><Citation>Robson B. COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles&#x2019; heel conserved region to minimize probability of escape mutations and drug resistance. Comput. Biol. Med. 2020, 121, 103749.10.1016/j.compbiomed.2020.103749.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.compbiomed.2020.103749</ArticleId><ArticleId IdType="pmc">PMC7151553</ArticleId><ArticleId IdType="pubmed">32568687</ArticleId></ArticleIdList></Reference><Reference><Citation>Robson B. Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus. Comput. Biol. Med. 2020, 119, 103670.10.1016/j.compbiomed.2020.103670.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.compbiomed.2020.103670</ArticleId><ArticleId IdType="pmc">PMC7094376</ArticleId><ArticleId IdType="pubmed">32209231</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledford H. Antibody therapies could be a bridge to a coronavirus vaccine - but will the world benefit?. Nature 2020, 584 (7821), 333&#x2013;334. 10.1038/d41586-020-02360-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-020-02360-y</ArticleId><ArticleId IdType="pubmed">32782402</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoof M.; Faust B.; Saunders R. A.; Sangwan S.; Rezelj V.; Hoppe N.; Boone M.; Billesbolle C. B.; Puchades C.; Azumaya C. M.; Kratochvil H. T.; Zimanyi M.; Deshpande I.; Liang J.; Dickinson S.; Nguyen H. C.; Chio C. M.; Merz G. E.; Thompson M. C.; Diwanji D.; Schaefer K.; Anand A. A.; Dobzinski N.; Zha B. S.; Simoneau C. R.; Leon K.; White K. M.; Chio U. S.; Gupta M.; Jin M.; Li F.; Liu Y.; Zhang K.; Bulkley D.; Sun M.; Smith A. M.; Rizo A. N.; Moss F.; Brilot A. F.; Pourmal S.; Trenker R.; Pospiech T.; Gupta S.; Barsi-Rhyne B.; Belyy V.; Barile-Hill A. W.; Nock S.; Liu Y.; Krogan N. J.; Ralston C. Y.; Swaney D. L.; Garcia-Sastre A.; Ott M.; Vignuzzi M.; Consortium Q. S. B.; Walter P.; Manglik A. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. Science 2020, 370 (6523), 1473&#x2013;1479. 10.1126/science.abe3255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abe3255</ArticleId><ArticleId IdType="pmc">PMC7857409</ArticleId><ArticleId IdType="pubmed">33154106</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao L.; Goreshnik I.; Coventry B.; Case J. B.; Miller L.; Kozodoy L.; Chen R. E.; Carter L.; Walls A. C.; Park Y. J.; Strauch E. M.; Stewart L.; Diamond M. S.; Veesler D.; Baker D. De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. Science 2020, 370 (6515), 426&#x2013;431. 10.1126/science.abd9909.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd9909</ArticleId><ArticleId IdType="pmc">PMC7857403</ArticleId><ArticleId IdType="pubmed">32907861</ArticleId></ArticleIdList></Reference><Reference><Citation>Detalle L.; Stohr T.; Palomo C.; Piedra P. A.; Gilbert B. E.; Mas V.; Millar A.; Power U. F.; Stortelers C.; Allosery K.; Melero J. A.; Depla E. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection. Antimicrob. Agents Chemother. 2016, 60 (1), 6&#x2013;13. 10.1128/AAC.01802-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01802-15</ArticleId><ArticleId IdType="pmc">PMC4704182</ArticleId><ArticleId IdType="pubmed">26438495</ArticleId></ArticleIdList></Reference><Reference><Citation>Chevalier A.; Silva D. A.; Rocklin G. J.; Hicks D. R.; Vergara R.; Murapa P.; Bernard S. M.; Zhang L.; Lam K. H.; Yao G.; Bahl C. D.; Miyashita S. I.; Goreshnik I.; Fuller J. T.; Koday M. T.; Jenkins C. M.; Colvin T.; Carter L.; Bohn A.; Bryan C. M.; Fernandez-Velasco D. A.; Stewart L.; Dong M.; Huang X.; Jin R.; Wilson I. A.; Fuller D. H.; Baker D. Massively parallel de novo protein design for targeted therapeutics. Nature 2017, 550 (7674), 74&#x2013;79. 10.1038/nature23912.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature23912</ArticleId><ArticleId IdType="pmc">PMC5802399</ArticleId><ArticleId IdType="pubmed">28953867</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung Y. H.; Beiss V.; Fiering S. N.; Steinmetz N. F. COVID-19 Vaccine Frontrunners and Their Nanotechnology Design. ACS Nano 2020, 14 (10), 12522&#x2013;12537. 10.1021/acsnano.0c07197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.0c07197</ArticleId><ArticleId IdType="pubmed">33034449</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi N.; Hogan M. J.; Porter F. W.; Weissman D. mRNA vaccines - a new era in vaccinology. Nat. Rev. Drug Discov 2018, 17 (4), 261&#x2013;279. 10.1038/nrd.2017.243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2017.243</ArticleId><ArticleId IdType="pmc">PMC5906799</ArticleId><ArticleId IdType="pubmed">29326426</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack F. P.; Thomas S. J.; Kitchin N.; Absalon J.; Gurtman A.; Lockhart S.; Perez J. L.; Perez Marc G.; Moreira E. D.; Zerbini C.; Bailey R.; Swanson K. A.; Roychoudhury S.; Koury K.; Li P.; Kalina W. V.; Cooper D.; Frenck R. W. Jr.; Hammitt L. L.; Tureci O.; Nell H.; Schaefer A.; Unal S.; Tresnan D. B.; Mather S.; Dormitzer P. R.; Sahin U.; Jansen K. U.; Gruber W. C.; Group C. C. T. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020, 383 (27), 2603&#x2013;2615. 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliver S. E.; Gargano J. W.; Marin M.; Wallace M.; Curran K. G.; Chamberland M.; McClung N.; Campos-Outcalt D.; Morgan R. L.; Mbaeyi S.; Romero J. R.; Talbot H. K.; Lee G. M.; Bell B. P.; Dooling K.. The Advisory Committee on Immunization Practices&#x2019; Interim Recommendation for Use of Moderna COVID-19 Vaccine&#x2014;United States, December 2020; Centers for Disease Control and Prevention, 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9191904</ArticleId><ArticleId IdType="pubmed">33382675</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulligan M. J.; Lyke K. E.; Kitchin N.; Absalon J.; Gurtman A.; Lockhart S.; Neuzil K.; Raabe V.; Bailey R.; Swanson K. A.; Li P.; Koury K.; Kalina W.; Cooper D.; Fontes-Garfias C.; Shi P. Y.; Tureci O.; Tompkins K. R.; Walsh E. E.; Frenck R.; Falsey A. R.; Dormitzer P. R.; Gruber W. C.; Sahin U.; Jansen K. U. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 2020, 586 (7830), 589&#x2013;593. 10.1038/s41586-020-2639-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2639-4</ArticleId><ArticleId IdType="pubmed">32785213</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan H.; Sun J.; Wang K.; Wang H.; Wu S.; Bao L.; He W.; Wang D.; Zhu A.; Zhang T.; Gao R.; Dong B.; Li J.; Yang L.; Zhong M.; Lv Q.; Qin F.; Zhuang Z.; Huang X.; Yang X.; Li Y.; Che Y.; Jiang J. Repurposing carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2. Acta Pharm. Sin B 2021, 11 (9), 2850&#x2013;2858. 10.1016/j.apsb.2021.02.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2021.02.024</ArticleId><ArticleId IdType="pmc">PMC7946546</ArticleId><ArticleId IdType="pubmed">33723501</ArticleId></ArticleIdList></Reference><Reference><Citation>Lima W. G.; Brito J. C. M.; Overhage J.; Nizer W. The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review. Arch. Virol. 2020, 165 (8), 1729&#x2013;1737. 10.1007/s00705-020-04693-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-020-04693-5</ArticleId><ArticleId IdType="pmc">PMC7276657</ArticleId><ArticleId IdType="pubmed">32514689</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S. Y.; Yau H. S.; Yu M. Y.; Tsang H. F.; Chan L. W. C.; Cho W. C. S.; Shing Yu A. C.; Yuen Yim A. K.; Li M. J. W.; Wong Y. K. E.; Pei X. M.; Cesar Wong S. C. The diagnostic methods in the COVID-19 pandemic, today and in the future. Expert Rev. Mol. Diagn 2020, 20 (9), 985&#x2013;993. 10.1080/14737159.2020.1816171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737159.2020.1816171</ArticleId><ArticleId IdType="pubmed">32845192</ArticleId></ArticleIdList></Reference><Reference><Citation>Esbin M. N.; Whitney O. N.; Chong S.; Maurer A.; Darzacq X.; Tjian R. Overcoming the bottleneck to widespread testing: a rapid review of nucleic acid testing approaches for COVID-19 detection. RNA 2020, 26 (7), 771&#x2013;783. 10.1261/rna.076232.120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1261/rna.076232.120</ArticleId><ArticleId IdType="pmc">PMC7297120</ArticleId><ArticleId IdType="pubmed">32358057</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith K. F.; Goldberg M.; Rosenthal S.; Carlson L.; Chen J.; Chen C.; Ramachandran S. Global rise in human infectious disease outbreaks. J. R Soc. Interface 2014, 11 (101), 20140950.10.1098/rsif.2014.0950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsif.2014.0950</ArticleId><ArticleId IdType="pmc">PMC4223919</ArticleId><ArticleId IdType="pubmed">25401184</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37626929</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>16</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Antisense Therapy for Infectious Diseases.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2119</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells12162119</ELocationID><Abstract><AbstractText>Infectious diseases, particularly Tuberculosis (TB) caused by <i>Mycobacterium tuberculosis</i>, pose a significant global health challenge, with 1.6 million reported deaths in 2021, making it the most fatal disease caused by a single infectious agent. The rise of drug-resistant infectious diseases adds to the urgency of finding effective and safe intervention therapies. Antisense therapy uses antisense oligonucleotides (ASOs) that are short, chemically modified, single-stranded deoxyribonucleotide molecules complementary to their mRNA target. Due to their designed target specificity and inhibition of a disease-causing gene at the mRNA level, antisense therapy has gained interest as a potential therapeutic approach. This type of therapy is currently utilized in numerous diseases, such as cancer and genetic disorders. Currently, there are limited but steadily increasing studies available that report on the use of ASOs as treatment for infectious diseases. This review explores the sustainability of FDA-approved and preclinically tested ASOs as a treatment for infectious diseases and the adaptability of ASOs for chemical modifications resulting in reduced side effects with improved drug delivery; thus, highlighting the potential therapeutic uses of ASOs for treating infectious diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Buthelezi</LastName><ForeName>Lwanda Abonga</ForeName><Initials>LA</Initials><Identifier Source="ORCID">0000-0001-5459-4826</Identifier><AffiliationInfo><Affiliation>International Centre for Genetic Engineering and Biotechnology, Cape Town Component, Cape Town 7925, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Division of Immunology, Institute of Infectious Diseases and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pillay</LastName><ForeName>Shandre</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>International Centre for Genetic Engineering and Biotechnology, Cape Town Component, Cape Town 7925, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Division of Immunology, Institute of Infectious Diseases and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ntuli</LastName><ForeName>Noxolo Nokukhanya</ForeName><Initials>NN</Initials><AffiliationInfo><Affiliation>International Centre for Genetic Engineering and Biotechnology, Cape Town Component, Cape Town 7925, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Division of Immunology, Institute of Infectious Diseases and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gcanga</LastName><ForeName>Lorna</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>International Centre for Genetic Engineering and Biotechnology, Cape Town Component, Cape Town 7925, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Division of Immunology, Institute of Infectious Diseases and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guler</LastName><ForeName>Reto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>International Centre for Genetic Engineering and Biotechnology, Cape Town Component, Cape Town 7925, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Division of Immunology, Institute of Infectious Diseases and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health Sciences, Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town 7925, South Africa.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AI160501</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003141" MajorTopicYN="Y">Communicable Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001691" MajorTopicYN="N">Biological Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009169" MajorTopicYN="Y">Mycobacterium tuberculosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016376" MajorTopicYN="N">Oligonucleotides, Antisense</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antisense oligonucleotide</Keyword><Keyword MajorTopicYN="N">antisense therapy</Keyword><Keyword MajorTopicYN="N">infectious disease</Keyword><Keyword MajorTopicYN="N">mRNA</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>28</Day><Hour>7</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>26</Day><Hour>10</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>26</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>8</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37626929</ArticleId><ArticleId IdType="pmc">PMC10453568</ArticleId><ArticleId IdType="doi">10.3390/cells12162119</ArticleId><ArticleId IdType="pii">cells12162119</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dhuri K., Bechtold C., Quijano E., Pham H., Gupta A., Vikram A., Bahal R. Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development. J. Clin. Med. 2020;9:2004. doi: 10.3390/jcm9062004.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9062004</ArticleId><ArticleId IdType="pmc">PMC7355792</ArticleId><ArticleId IdType="pubmed">32604776</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts T.C., Langer R., Wood M.J.A. Advances in oligonucleotide drug delivery. Nat. Rev. Drug Discov. 2020;19:673&#x2013;694. doi: 10.1038/s41573-020-0075-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-020-0075-7</ArticleId><ArticleId IdType="pmc">PMC7419031</ArticleId><ArticleId IdType="pubmed">32782413</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh N.N., Luo D., Singh R.N. Pre-mRNA Splicing Modulation by Antisense Oligonucleotides. Methods Mol. Biol. 2018;1828:415&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6195309</ArticleId><ArticleId IdType="pubmed">30171557</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang X.H., Sun H., Shen W., Wang S., Yao J., Migawa M.T., Bui H.-H., Damle S.S., Riney S., Graham M.J., et al. Antisense oligonucleotides targeting translation inhibitory elements in 5&#x2019; UTRs can selectively increase protein levels. Nucleic Acids Res. 2017;45:9528&#x2013;9546. doi: 10.1093/nar/gkx632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx632</ArticleId><ArticleId IdType="pmc">PMC5766168</ArticleId><ArticleId IdType="pubmed">28934489</ArticleId></ArticleIdList></Reference><Reference><Citation>Arechavala-Gomeza V., Garanto A. Antisense RNA Therapeutics: A Brief Overview. Methods Mol. Biol. 2022;2434:33&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9703294</ArticleId><ArticleId IdType="pubmed">35213008</ArticleId></ArticleIdList></Reference><Reference><Citation>Vickers T.A., Crooke S.T. The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA. Nucleic Acids Res. 2015;43:8955&#x2013;8963. doi: 10.1093/nar/gkv920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv920</ArticleId><ArticleId IdType="pmc">PMC4605327</ArticleId><ArticleId IdType="pubmed">26384424</ArticleId></ArticleIdList></Reference><Reference><Citation>Chery J. RNA therapeutics: RNAi and antisense mechanisms and clinical applications. Postdoc. J. 2016;4:35&#x2013;50. doi: 10.14304/SURYA.JPR.V4N7.5.</Citation><ArticleIdList><ArticleId IdType="doi">10.14304/SURYA.JPR.V4N7.5</ArticleId><ArticleId IdType="pmc">PMC4995773</ArticleId><ArticleId IdType="pubmed">27570789</ArticleId></ArticleIdList></Reference><Reference><Citation>McNally E.M., Wyatt E.J. Welcome to the splice age: Antisense oligonucleotide-mediated exon skipping gains wider applicability. J. Clin. Investig. 2016;126:1236&#x2013;1238. doi: 10.1172/JCI86799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI86799</ArticleId><ArticleId IdType="pmc">PMC4811139</ArticleId><ArticleId IdType="pubmed">26999602</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua Y., Krainer A.R. Antisense-mediated exon inclusion. Methods Mol. Biol. 2012;867:307&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3390937</ArticleId><ArticleId IdType="pubmed">22454070</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan J.H., Lim S., Wong W.S. Antisense oligonucleotides: From design to therapeutic application. Clin. Exp. Pharmacol. Physiol. 2006;33:533&#x2013;540. doi: 10.1111/j.1440-1681.2006.04403.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1681.2006.04403.x</ArticleId><ArticleId IdType="pubmed">16700890</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts J.K., Corey D.R. Silencing disease genes in the laboratory and the clinic. J. Pathol. 2012;226:365&#x2013;379. doi: 10.1002/path.2993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.2993</ArticleId><ArticleId IdType="pmc">PMC3916955</ArticleId><ArticleId IdType="pubmed">22069063</ArticleId></ArticleIdList></Reference><Reference><Citation>McClorey G., Wood M.J. An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies. Curr. Opin. Pharmacol. 2015;24:52&#x2013;58. doi: 10.1016/j.coph.2015.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2015.07.005</ArticleId><ArticleId IdType="pubmed">26277332</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarn W.Y., Cheng Y., Ko S.H., Huang L.M. Antisense Oligonucleotide-Based Therapy of Viral Infections. Pharmaceutics. 2021;13:2015. doi: 10.3390/pharmaceutics13122015.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics13122015</ArticleId><ArticleId IdType="pmc">PMC8707165</ArticleId><ArticleId IdType="pubmed">34959297</ArticleId></ArticleIdList></Reference><Reference><Citation>Crooke S.T., Baker B.F., Crooke R.M., Liang X.H. Antisense technology: An overview and prospectus. Nat. Rev. Drug Discov. 2021;20:427&#x2013;453. doi: 10.1038/s41573-021-00162-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-021-00162-z</ArticleId><ArticleId IdType="pubmed">33762737</ArticleId></ArticleIdList></Reference><Reference><Citation>Crooke S.T., Vickers T.A., Liang X.H. Phosphorothioate modified oligonucleotide-protein interactions. Nucleic Acids Res. 2020;48:5235&#x2013;5253. doi: 10.1093/nar/gkaa299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkaa299</ArticleId><ArticleId IdType="pmc">PMC7261153</ArticleId><ArticleId IdType="pubmed">32356888</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagliardi M., Ashizawa A.T. The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery. Biomedicines. 2021;9:433. doi: 10.3390/biomedicines9040433.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9040433</ArticleId><ArticleId IdType="pmc">PMC8072990</ArticleId><ArticleId IdType="pubmed">33923688</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Global Tuberculosis Report 2022. World Health Organization; Geneva, Switzerland: 2022.</Citation></Reference><Reference><Citation>Streicher L.M. Exploring the future of infectious disease treatment in a post-antibiotic era: A comparative review of alternative therapeutics. J. Glob. Antimicrob. Resist. 2021;24:285&#x2013;295. doi: 10.1016/j.jgar.2020.12.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jgar.2020.12.025</ArticleId><ArticleId IdType="pubmed">33484895</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephenson M.L., Zamecnik P.C. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc. Natl. Acad. Sci. USA. 1978;75:285&#x2013;288. doi: 10.1073/pnas.75.1.285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.75.1.285</ArticleId><ArticleId IdType="pmc">PMC411231</ArticleId><ArticleId IdType="pubmed">75546</ArticleId></ArticleIdList></Reference><Reference><Citation>Spurgers K.B., Sharkey C.M., Warfield K.L., Bavari S. Oligonucleotide antiviral therapeutics: Antisense and RNA interference for highly pathogenic RNA viruses. Antivir. Res. 2008;78:26&#x2013;36. doi: 10.1016/j.antiviral.2007.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2007.12.008</ArticleId><ArticleId IdType="pmc">PMC7114189</ArticleId><ArticleId IdType="pubmed">18258313</ArticleId></ArticleIdList></Reference><Reference><Citation>Guler R., Brombacher F. Host-directed drug therapy for tuberculosis. Nat. Chem. Biol. 2015;11:748&#x2013;751. doi: 10.1038/nchembio.1917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.1917</ArticleId><ArticleId IdType="pubmed">26379013</ArticleId></ArticleIdList></Reference><Reference><Citation>Guler R., Ozturk M., Sabeel S., Motaung B., Parihar S.P., Thienemann F., Brombacher F. Targeting Molecular Inflammatory Pathways in Granuloma as Host-Directed Therapies for Tuberculosis. Front. Immunol. 2021;12:733853. doi: 10.3389/fimmu.2021.733853.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.733853</ArticleId><ArticleId IdType="pmc">PMC8563828</ArticleId><ArticleId IdType="pubmed">34745105</ArticleId></ArticleIdList></Reference><Reference><Citation>Damase T.R., Sukhovershin R., Boada C., Taraballi F., Pettigrew R.I., Cooke J.P. The Limitless Future of RNA Therapeutics. Front. Bioeng. Biotechnol. 2021;9:628137. doi: 10.3389/fbioe.2021.628137.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fbioe.2021.628137</ArticleId><ArticleId IdType="pmc">PMC8012680</ArticleId><ArticleId IdType="pubmed">33816449</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowdy S.F. Overcoming cellular barriers for RNA therapeutics. Nat. Biotechnol. 2017;35:222&#x2013;229. doi: 10.1038/nbt.3802.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3802</ArticleId><ArticleId IdType="pubmed">28244992</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett C.F., Baker B.F., Pham N., Swayze E., Geary R.S. Pharmacology of Antisense Drugs. Annu. Rev. Pharmacol. Toxicol. 2017;57:81&#x2013;105. doi: 10.1146/annurev-pharmtox-010716-104846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pharmtox-010716-104846</ArticleId><ArticleId IdType="pubmed">27732800</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckstein F. Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid Ther. 2014;24:374&#x2013;387. doi: 10.1089/nat.2014.0506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/nat.2014.0506</ArticleId><ArticleId IdType="pubmed">25353652</ArticleId></ArticleIdList></Reference><Reference><Citation>Furdon P.J., Dominski Z., Kole R. RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds. Nucleic Acids Res. 1989;17:9193&#x2013;9204. doi: 10.1093/nar/17.22.9193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/17.22.9193</ArticleId><ArticleId IdType="pmc">PMC335124</ArticleId><ArticleId IdType="pubmed">2555787</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen W., De Hoyos C.L., Migawa M.T., Vickers T.A., Sun H., Low A., Bell T.A., Rahdar M., Mukhopadhyay S., Hart C.E., et al. Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index. Nat. Biotechnol. 2019;37:640&#x2013;650. doi: 10.1038/s41587-019-0106-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-019-0106-2</ArticleId><ArticleId IdType="pubmed">31036929</ArticleId></ArticleIdList></Reference><Reference><Citation>Miroshnichenko S.K., Patutina O.A., Burakova E.A., Chelobanov B.P., Fokina A.A., Vlassov V.V., Altman S., Zenkova M.A., Stetsenko D.A. Mesyl phosphoramidate antisense oligonucleotides as an alternative to phosphorothioates with improved biochemical and biological properties. Proc. Natl. Acad. Sci. USA. 2019;116:1229&#x2013;1234. doi: 10.1073/pnas.1813376116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1813376116</ArticleId><ArticleId IdType="pmc">PMC6347720</ArticleId><ArticleId IdType="pubmed">30622178</ArticleId></ArticleIdList></Reference><Reference><Citation>Scoles D.R., Minikel E.V., Pulst S.M. Antisense oligonucleotides: A primer. Neurol Genet. 2019;5:e323. doi: 10.1212/NXG.0000000000000323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000323</ArticleId><ArticleId IdType="pmc">PMC6501637</ArticleId><ArticleId IdType="pubmed">31119194</ArticleId></ArticleIdList></Reference><Reference><Citation>Sproat B.S., Lamond A.I., Beijer B., Neuner P., Ryder U. Highly efficient chemical synthesis of 2&#x2019;-O-methyloligoribonucleotides and tetrabiotinylated derivatives; novel probes that are resistant to degradation by RNA or DNA specific nucleases. Nucleic Acids Res. 1989;17:3373&#x2013;3386. doi: 10.1093/nar/17.9.3373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/17.9.3373</ArticleId><ArticleId IdType="pmc">PMC317781</ArticleId><ArticleId IdType="pubmed">2726482</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal S., Jiang Z., Zhao Q., Shaw D., Cai Q., Roskey A., Channavajjala L., Saxinger C., Zhang R. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies. Proc. Natl. Acad. Sci. USA. 1997;94:2620&#x2013;2625. doi: 10.1073/pnas.94.6.2620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.94.6.2620</ArticleId><ArticleId IdType="pmc">PMC20138</ArticleId><ArticleId IdType="pubmed">9122245</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuen M.F., Heo J., Jang J.W., Yoon J.H., Kweon Y.O., Park S.J., Bennett C.F., Kwoh T.J. Phase 2a, Randomized, double-blind, placebo controlled study of an antisense inhibitor (ISIS 505358) in treatment-naive Chronic Hepatitis B (CHB) patients: Safety and Antiviral efficacy. Hepatology. 2019;70:437a&#x2013;438a.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Nan Y., Zhang Y.J. Antisense Phosphorodiamidate Morpholino Oligomers as Novel Antiviral Compounds. Front. Microbiol. 2018;9:750. doi: 10.3389/fmicb.2018.00750.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2018.00750</ArticleId><ArticleId IdType="pmc">PMC5920040</ArticleId><ArticleId IdType="pubmed">29731743</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh S.Y., Ju Y., Park H. A highly effective and long-lasting inhibition of miRNAs with PNA-based antisense oligonucleotides. Mol. Cells. 2009;28:341&#x2013;345. doi: 10.1007/s10059-009-0134-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10059-009-0134-8</ArticleId><ArticleId IdType="pubmed">19812898</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagedorn P.H., Persson R., Funder E.D., Albaek N., Diemer S.L., Hansen D.J., M&#xf8;ller M.R., Papargyri N., Christiansen H., Hansen B.R., et al. Locked nucleic acid: Modality, diversity, and drug discovery. Drug Discov. Today. 2018;23:101&#x2013;114. doi: 10.1016/j.drudis.2017.09.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2017.09.018</ArticleId><ArticleId IdType="pubmed">28988994</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundin K.E., Gissberg O., Smith C.I.E., Zain R. Chemical Development of Therapeutic Oligonucleotides. Methods Mol. Biol. 2019;2036:3&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">31410788</ArticleId></ArticleIdList></Reference><Reference><Citation>Ottosen S., Parsley T.B., Yang L., Zeh K., van Doorn L.J., van der Veer E., Raney A.K., Hodges M.R., Patick A.K. In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122. Antimicrob. Agents Chemother. 2015;59:599&#x2013;608. doi: 10.1128/AAC.04220-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.04220-14</ArticleId><ArticleId IdType="pmc">PMC4291405</ArticleId><ArticleId IdType="pubmed">25385103</ArticleId></ArticleIdList></Reference><Reference><Citation>Springer A.D., Dowdy S.F. GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics. Nucleic Acid Ther. 2018;28:109&#x2013;118. doi: 10.1089/nat.2018.0736.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/nat.2018.0736</ArticleId><ArticleId IdType="pmc">PMC5994659</ArticleId><ArticleId IdType="pubmed">29792572</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond S.M., Aartsma-Rus A., Alves S., Borgos S.E., Buijsen R.A.M., Collin R.W.J., Covello G., Denti M.A., Desviat L.R., Echevarr&#xed;a L., et al. Delivery of oligonucleotide-based therapeutics: Challenges and opportunities. EMBO Mol. Med. 2021;13:e13243. doi: 10.15252/emmm.202013243.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.202013243</ArticleId><ArticleId IdType="pmc">PMC8033518</ArticleId><ArticleId IdType="pubmed">33821570</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J., Bi Y., Zhang H., Dong S., Teng L., Lee R.J., Yang Z. Cell-Penetrating Peptides in Diagnosis and Treatment of Human Diseases: From Preclinical Research to Clinical Application. Front. Pharmacol. 2020;11:697. doi: 10.3389/fphar.2020.00697.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.00697</ArticleId><ArticleId IdType="pmc">PMC7251059</ArticleId><ArticleId IdType="pubmed">32508641</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayraklioglu N., Horuluoglu B., Klinman D.M. CpG Oligonucleotides as Vaccine Adjuvants. Methods Mol. Biol. 2021;2197:51&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">32827132</ArticleId></ArticleIdList></Reference><Reference><Citation>Copolovici D.M., Langel K., Eriste E., Langel U. Cell-penetrating peptides: Design, synthesis, and applications. ACS Nano. 2014;8:1972&#x2013;1994. doi: 10.1021/nn4057269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/nn4057269</ArticleId><ArticleId IdType="pubmed">24559246</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni S., Zhuo Z., Pan Y., Yu Y., Li F., Liu J., Wang L., Wu X., Li D., Wan Y., et al. Recent Progress in Aptamer Discoveries and Modifications for Therapeutic Applications. ACS Appl. Mater. Interfaces. 2021;13:9500&#x2013;9519. doi: 10.1021/acsami.0c05750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsami.0c05750</ArticleId><ArticleId IdType="pubmed">32603135</ArticleId></ArticleIdList></Reference><Reference><Citation>Prakash T.P., Graham M.J., Yu J., Carty R., Low A., Chappell A., Schmidt K., Zhao C., Aghajan M., Murray H.F., et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res. 2014;42:8796&#x2013;8807. doi: 10.1093/nar/gku531.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gku531</ArticleId><ArticleId IdType="pmc">PMC4117763</ArticleId><ArticleId IdType="pubmed">24992960</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuen M.F., Heo J., Kumada H., Suzuki F., Suzuki Y., Xie Q., Jia J., Karino Y., Hou J., Chayama K., et al. Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy. J. Hepatol. 2022;77:967&#x2013;977. doi: 10.1016/j.jhep.2022.05.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2022.05.031</ArticleId><ArticleId IdType="pubmed">35714812</ArticleId></ArticleIdList></Reference><Reference><Citation>Daraee H., Etemadi A., Kouhi M., Alimirzalu S., Akbarzadeh A. Application of liposomes in medicine and drug delivery. Artif. Cells Nanomed. Biotechnol. 2016;44:381&#x2013;391. doi: 10.3109/21691401.2014.953633.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21691401.2014.953633</ArticleId><ArticleId IdType="pubmed">25222036</ArticleId></ArticleIdList></Reference><Reference><Citation>New R.R., Chance M.L., Thomas S.C., Peters W. Antileishmanial activity of antimonials entrapped in liposomes. Nature. 1978;272:55&#x2013;56. doi: 10.1038/272055a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/272055a0</ArticleId><ArticleId IdType="pubmed">203863</ArticleId></ArticleIdList></Reference><Reference><Citation>Tagami T., Ozeki T. Recent Trends in Clinical Trials Related to Carrier-Based Drugs. J. Pharm. Sci. 2017;106:2219&#x2013;2226. doi: 10.1016/j.xphs.2017.02.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xphs.2017.02.026</ArticleId><ArticleId IdType="pubmed">28259767</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J., Hu C., Moufawad El Achkar C., Black L.E., Douville J., Larson A., Pendergast M.K., Goldkind S.F., Lee E.A., Kuniholm A., et al. Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease. N. Engl. J. Med. 2019;381:1644&#x2013;1652. doi: 10.1056/NEJMoa1813279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1813279</ArticleId><ArticleId IdType="pmc">PMC6961983</ArticleId><ArticleId IdType="pubmed">31597037</ArticleId></ArticleIdList></Reference><Reference><Citation>Gheibi-Hayat S.M., Jamialahmadi K. Antisense Oligonucleotide (AS-ODN) Technology: Principle, Mechanism and Challenges. Biotechnol. Appl. Biochem. 2021;68:1086&#x2013;1094. doi: 10.1002/bab.2028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bab.2028</ArticleId><ArticleId IdType="pubmed">32964539</ArticleId></ArticleIdList></Reference><Reference><Citation>Vickers T.A., Crooke S.T. Antisense oligonucleotides capable of promoting specific target mRNA reduction via competing RNase H1-dependent and independent mechanisms. PLoS ONE. 2014;9:e108625. doi: 10.1371/journal.pone.0108625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0108625</ArticleId><ArticleId IdType="pmc">PMC4191969</ArticleId><ArticleId IdType="pubmed">25299183</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishina K., Piao W., Yoshida-Tanaka K., Sujino Y., Nishina T., Yamamoto T., Nitta K., Yoshioka K., Kuwahara H., Yasuhara H., et al. DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencing. Nat. Commun. 2015;6:7969. doi: 10.1038/ncomms8969.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms8969</ArticleId><ArticleId IdType="pmc">PMC4918363</ArticleId><ArticleId IdType="pubmed">26258894</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H., Lima W.F., Zhang H., Fan A., Sun H., Crooke S.T. Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J. Biol. Chem. 2004;279:17181&#x2013;17189. doi: 10.1074/jbc.M311683200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M311683200</ArticleId><ArticleId IdType="pubmed">14960586</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerritelli S.M., Crouch R.J. Ribonuclease H: The enzymes in eukaryotes. FEBS J. 2009;276:1494&#x2013;1505. doi: 10.1111/j.1742-4658.2009.06908.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-4658.2009.06908.x</ArticleId><ArticleId IdType="pmc">PMC2746905</ArticleId><ArticleId IdType="pubmed">19228196</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y. Drug Discovery Perspectives of Antisense Oligonucleotides. Biomol. Ther. 2023;31:241&#x2013;252. doi: 10.4062/biomolther.2023.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.4062/biomolther.2023.001</ArticleId><ArticleId IdType="pmc">PMC10129852</ArticleId><ArticleId IdType="pubmed">36859811</ArticleId></ArticleIdList></Reference><Reference><Citation>Echevarria L., Aupy P., Goyenvalle A. Exon-skipping advances for Duchenne muscular dystrophy. Hum. Mol. Genet. 2018;27:R163&#x2013;R172. doi: 10.1093/hmg/ddy171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddy171</ArticleId><ArticleId IdType="pubmed">29771317</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald C.M., Shieh P.B., Abdel-Hamid H.Z., Connolly A.M., Ciafaloni E., Wagner K.R., Goemans N., Mercuri E., Khan N., Koenig E., et al. Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial. J. Neuromuscul. Dis. 2021;8:989&#x2013;1001. doi: 10.3233/JND-210643.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JND-210643</ArticleId><ArticleId IdType="pmc">PMC8673535</ArticleId><ArticleId IdType="pubmed">34120909</ArticleId></ArticleIdList></Reference><Reference><Citation>Servais L., Mercuri E., Straub V., Guglieri M., Seferian A.M., Scoto M., Leone D., Koenig E., Khan N., Dugar A., et al. Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial. Nucleic Acid Ther. 2022;32:29&#x2013;39. doi: 10.1089/nat.2021.0043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/nat.2021.0043</ArticleId><ArticleId IdType="pmc">PMC8817703</ArticleId><ArticleId IdType="pubmed">34788571</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner K.R., Kuntz N.L., Koenig E., East L., Upadhyay S., Han B., Shieh P.B. Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double-blind, placebo-controlled, dose-titration trial. Muscle Nerve. 2021;64:285&#x2013;292. doi: 10.1002/mus.27347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27347</ArticleId><ArticleId IdType="pmc">PMC9290993</ArticleId><ArticleId IdType="pubmed">34105177</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua Y., Vickers T.A., Baker B.F., Bennett C.F., Krainer A.R. Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol. 2007;5:e73. doi: 10.1371/journal.pbio.0050073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.0050073</ArticleId><ArticleId IdType="pmc">PMC1820610</ArticleId><ArticleId IdType="pubmed">17355180</ArticleId></ArticleIdList></Reference><Reference><Citation>Roehr B. Fomivirsen approved for CMV retinitis. J. Int. Assoc. Physicians AIDS Care. 1998;4:14&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">11365956</ArticleId></ArticleIdList></Reference><Reference><Citation>Schottstedt V., Blumel J., Burger R., Drosten C., Groner A., Gurtler L., Heiden M., Hildebrandt M., Jansen B., Montag-Lessing T., et al. Human Cytomegalovirus (HCMV)&#x2014;Revised. Transfus. Med. Hemother. 2010;37:365&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3048947</ArticleId><ArticleId IdType="pubmed">21483467</ArticleId></ArticleIdList></Reference><Reference><Citation>De Smet M.D., Meenken C.J., van den Horn G.J. Fomivirsen&#x2014;A phosphorothioate oligonucleotide for the treatment of CMV retinitis. Ocul. Immunol. Inflamm. 1999;7:189&#x2013;198. doi: 10.1076/ocii.7.3.189.4007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1076/ocii.7.3.189.4007</ArticleId><ArticleId IdType="pubmed">10611727</ArticleId></ArticleIdList></Reference><Reference><Citation>Geary R.S., Henry S.P., Grillone L.R. Fomivirsen: Clinical pharmacology and potential drug interactions. Clin. Pharmacokinet. 2002;41:255&#x2013;260. doi: 10.2165/00003088-200241040-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003088-200241040-00002</ArticleId><ArticleId IdType="pubmed">11978144</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry C.M., Balfour J.A. Fomivirsen. Drugs. 1999;57 doi: 10.2165/00003495-199957030-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003495-199957030-00010</ArticleId><ArticleId IdType="pubmed">10193689</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitravene Study Group A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am. J. Ophthalmol. 2002;133:467&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pubmed">11931780</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan X.X., Actor J.K., Chen Y. Peptide nucleic acid antisense oligomer as a therapeutic strategy against bacterial infection: Proof of principle using mouse intraperitoneal infection. Antimicrob. Agents Chemother. 2005;49:3203&#x2013;3207. doi: 10.1128/AAC.49.8.3203-3207.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.49.8.3203-3207.2005</ArticleId><ArticleId IdType="pmc">PMC1196239</ArticleId><ArticleId IdType="pubmed">16048926</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayaraman K., McParland K., Miller P., Ts&#x2019;o P.O. Selective inhibition of Escherichia coli protein synthesis and growth by nonionic oligonucleotides complementary to the 3&#x2019; end of 16S rRNA. Proc. Natl. Acad. Sci. USA. 1981;78:1537&#x2013;1541. doi: 10.1073/pnas.78.3.1537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.78.3.1537</ArticleId><ArticleId IdType="pmc">PMC319166</ArticleId><ArticleId IdType="pubmed">6165012</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauss T., Arpin C., Bientz L., Vinh Nguyen P., Vialet B., Benizri S., Barth&#xe9;l&#xe9;my P. Lipid oligonucleotides as a new strategy for tackling the antibiotic resistance. Sci. Rep. 2020;10:1054. doi: 10.1038/s41598-020-58047-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-58047-x</ArticleId><ArticleId IdType="pmc">PMC6978458</ArticleId><ArticleId IdType="pubmed">31974472</ArticleId></ArticleIdList></Reference><Reference><Citation>Goh S., Loeffler A., Lloyd D.H., Nair S.P., Good L. Oxacillin sensitization of methicillin-resistant Staphylococcus aureus and methicillin-resistant Staphylococcus pseudintermedius by antisense peptide nucleic acids in vitro. BMC Microbiol. 2015;15:262. doi: 10.1186/s12866-015-0599-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12866-015-0599-x</ArticleId><ArticleId IdType="pmc">PMC4642645</ArticleId><ArticleId IdType="pubmed">26560174</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegarty J.P., Stewart Sr D.B. Advances in therapeutic bacterial antisense biotechnology. Appl. Microbiol. Biotechnol. 2018;102:1055&#x2013;1065. doi: 10.1007/s00253-017-8671-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00253-017-8671-0</ArticleId><ArticleId IdType="pmc">PMC5777866</ArticleId><ArticleId IdType="pubmed">29209794</ArticleId></ArticleIdList></Reference><Reference><Citation>Otsuka T., Brauer A.L., Kirkham C., Sully E.K., Pettigrew M.M., Kong Y., Geller B.L., Murphy T.F. Antimicrobial activity of antisense peptide-peptide nucleic acid conjugates against non-typeable Haemophilus influenzae in planktonic and biofilm forms. J. Antimicrob. Chemother. 2017;72:137&#x2013;144. doi: 10.1093/jac/dkw384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkw384</ArticleId><ArticleId IdType="pmc">PMC5161047</ArticleId><ArticleId IdType="pubmed">27986898</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard J.J., Sturge C.R., Moustafa D.A., Daly S.M., Marshall-Batty K.R., Felder C.F., Zamora D., Yabe-Gill M., Labandeira-Rey M., Bailey S.M., et al. Inhibition of Pseudomonas aeruginosa by Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers. Antimicrob. Agents Chemother. 2017;61:e01938-16. doi: 10.1128/AAC.01938-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01938-16</ArticleId><ArticleId IdType="pmc">PMC5365667</ArticleId><ArticleId IdType="pubmed">28137807</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang S., He Y., Xia Y., Wang H., Wang L., Gao R., Zhang M. Inhibiting the growth of methicillin-resistant Staphylococcus aureus in vitro with antisense peptide nucleic acid conjugates targeting the ftsZ gene. Int. J. Infect. Dis. 2015;30:1&#x2013;6. doi: 10.1016/j.ijid.2014.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2014.09.015</ArticleId><ArticleId IdType="pubmed">25447735</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng J., Da F., Ma X., Wang N., Wang Y., Zhang H., Li M., Zhou Y., Xue X., Hou Z., et al. Antisense growth inhibition of methicillin-resistant Staphylococcus aureus by locked nucleic acid conjugated with cell-penetrating peptide as a novel FtsZ inhibitor. Antimicrob. Agents Chemother. 2015;59:914&#x2013;922. doi: 10.1128/AAC.03781-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.03781-14</ArticleId><ArticleId IdType="pmc">PMC4335876</ArticleId><ArticleId IdType="pubmed">25421468</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawyer A.J., Wesolowski D., Gandotra N., Stojadinovic A., Izadjoo M., Altman S., Kyriakides T.R. A peptide-morpholino oligomer conjugate targeting Staphylococcus aureus gyrA mRNA improves healing in an infected mouse cutaneous wound model. Int. J. Pharm. 2013;453:651&#x2013;655. doi: 10.1016/j.ijpharm.2013.05.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2013.05.041</ArticleId><ArticleId IdType="pmc">PMC3756894</ArticleId><ArticleId IdType="pubmed">23727592</ArticleId></ArticleIdList></Reference><Reference><Citation>Alajlouni R.A., Seleem M.N. Targeting Listeria monocytogenes rpoA and rpoD genes using peptide nucleic acids. Nucleic Acid Ther. 2013;23:363&#x2013;367. doi: 10.1089/nat.2013.0426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/nat.2013.0426</ArticleId><ArticleId IdType="pmc">PMC3760085</ArticleId><ArticleId IdType="pubmed">23859300</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajasekaran P., Alexander J.C., Seleem M.N., Jain N., Sriranganathan N., Wattam A.R., Setubal J.C., Boyle S.M. Peptide nucleic acids inhibit growth of Brucella suis in pure culture and in infected murine macrophages. Int. J. Antimicrob. Agents. 2013;41:358&#x2013;362. doi: 10.1016/j.ijantimicag.2012.11.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2012.11.017</ArticleId><ArticleId IdType="pmc">PMC3834731</ArticleId><ArticleId IdType="pubmed">23305655</ArticleId></ArticleIdList></Reference><Reference><Citation>Geller B.L., Marshall-Batty K., Schnell F.J., McKnight M.M., Iversen P.L., Greenberg D.E. Gene-silencing antisense oligomers inhibit acinetobacter growth in vitro and in vivo. J. Infect. Dis. 2013;208:1553&#x2013;1560. doi: 10.1093/infdis/jit460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit460</ArticleId><ArticleId IdType="pmc">PMC3805245</ArticleId><ArticleId IdType="pubmed">24130069</ArticleId></ArticleIdList></Reference><Reference><Citation>Holden K.L., Stein D.A., Pierson T.C., Ahmed A.A., Clyde K., Iversen P.L., Harris E. Inhibition of dengue virus translation and RNA synthesis by a morpholino oligomer targeted to the top of the terminal 3&#x2019; stem-loop structure. Virology. 2006;344:439&#x2013;452. doi: 10.1016/j.virol.2005.08.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2005.08.034</ArticleId><ArticleId IdType="pubmed">16214197</ArticleId></ArticleIdList></Reference><Reference><Citation>Phumesin P., Junking M., Panya A., Yongpitakwattana P., Noisakran S., Limjindaporn T., Yenchitsomanus P.-T. Inhibition of dengue virus replication in monocyte-derived dendritic cells by vivo-morpholino oligomers. Virus Res. 2019;260:123&#x2013;128. doi: 10.1016/j.virusres.2018.11.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2018.11.014</ArticleId><ArticleId IdType="pubmed">30503719</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai S.H., Stein D.A., Guerrero-Plata A., Liao S.L., Ivanciuc T., Hong C., Iversen P.L., Casola A., Garofalo R.P. Inhibition of respiratory syncytial virus infections with morpholino oligomers in cell cultures and in mice. Mol. Ther. 2008;16:1120&#x2013;1128. doi: 10.1038/mt.2008.81.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2008.81</ArticleId><ArticleId IdType="pmc">PMC2782410</ArticleId><ArticleId IdType="pubmed">18443602</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge Q., Pastey M., Kobasa D., Puthavathana P., Lupfer C., Bestwick R.K., Iversen P.L., Chen J., Stein D.A. Inhibition of multiple subtypes of influenza A virus in cell cultures with morpholino oligomers. Antimicrob. Agents Chemother. 2006;50:3724&#x2013;3733. doi: 10.1128/AAC.00644-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00644-06</ArticleId><ArticleId IdType="pmc">PMC1635187</ArticleId><ArticleId IdType="pubmed">16966399</ArticleId></ArticleIdList></Reference><Reference><Citation>Swenson D.L., Warfield K.L., Warren T.K., Lovejoy C., Hassinger J.N., Ruthel G., Blouch R.E., Moulton H.M., Weller D.D., Iversen P.L., et al. Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection. Antimicrob. Agents Chemother. 2009;53:2089&#x2013;2099. doi: 10.1128/AAC.00936-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00936-08</ArticleId><ArticleId IdType="pmc">PMC2681561</ArticleId><ArticleId IdType="pubmed">19223614</ArticleId></ArticleIdList></Reference><Reference><Citation>Javanbakht H., Mueller H., Walther J., Zhou X., Lopez A., Pattupara T., Blaising J., Pedersen L., Alb&#xe6;k N., Jackerott M., et al. Liver-Targeted Anti-HBV Single-Stranded Oligonucleotides with Locked Nucleic Acid Potently Reduce HBV Gene Expression In Vivo. Mol. Ther. Nucleic Acids. 2018;11:441&#x2013;454. doi: 10.1016/j.omtn.2018.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2018.02.005</ArticleId><ArticleId IdType="pmc">PMC5992345</ArticleId><ArticleId IdType="pubmed">29858079</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi M., Li H., Zhou J., Chomchan P., Aishwarya V., Damha M.J., Rossi J.J. Dual Mechanisms of Action of Self-Delivering, Anti-HIV-1 FANA Oligonucleotides as a Potential New Approach to HIV Therapy. Mol. Ther. Nucleic Acids. 2019;17:615&#x2013;625. doi: 10.1016/j.omtn.2019.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2019.07.001</ArticleId><ArticleId IdType="pmc">PMC6695270</ArticleId><ArticleId IdType="pubmed">31394430</ArticleId></ArticleIdList></Reference><Reference><Citation>Holden K.L., Harris E. Enhancement of dengue virus translation: Role of the 3&#x2019; untranslated region and the terminal 3&#x2019; stem-loop domain. Virology. 2004;329:119&#x2013;133. doi: 10.1016/j.virol.2004.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2004.08.004</ArticleId><ArticleId IdType="pubmed">15476880</ArticleId></ArticleIdList></Reference><Reference><Citation>You S., Padmanabhan R. A novel in vitro replication system for Dengue virus. Initiation of RNA synthesis at the 3&#x2019;-end of exogenous viral RNA templates requires 5&#x2019;- and 3&#x2019;-terminal complementary sequence motifs of the viral RNA. J. Biol. Chem. 1999;274:33714&#x2013;33722. doi: 10.1074/jbc.274.47.33714.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.274.47.33714</ArticleId><ArticleId IdType="pubmed">10559263</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg A., Wesolowski D., Alonso D., Deitsch K.W., Ben Mamoun C., Altman S. Targeting protein translation, RNA splicing, and degradation by morpholino-based conjugates in Plasmodium falciparum. Proc. Natl. Acad. Sci. USA. 2015;112:11935&#x2013;11940. doi: 10.1073/pnas.1515864112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1515864112</ArticleId><ArticleId IdType="pmc">PMC4586866</ArticleId><ArticleId IdType="pubmed">26351679</ArticleId></ArticleIdList></Reference><Reference><Citation>Witola W.H., Bauman B., McHugh M., Matthews K. Silencing of GRA10 protein expression inhibits Toxoplasma gondii intracellular growth and development. Parasitol. Int. 2014;63:651&#x2013;658. doi: 10.1016/j.parint.2014.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parint.2014.05.001</ArticleId><ArticleId IdType="pubmed">24832208</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto M., Nara T., Hirawake H., Morales J., Enomoto M., Mikoshiba K. Antisense oligonucleotides targeting parasite inositol 1,4,5-trisphosphate receptor inhibits mammalian host cell invasion by Trypanosoma cruzi. Sci. Rep. 2014;4:4231. doi: 10.1038/srep04231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep04231</ArticleId><ArticleId IdType="pmc">PMC3937783</ArticleId><ArticleId IdType="pubmed">24577136</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahan-Pasternak N., Nasereddin A., Kolevzon N., Pe&#x2019;er M., Wong W., Shinder V., Turnbull L., Whitchurch C.B., Elbaum M., Gilberger T.W., et al. PfSec13 is an unusual chromatin-associated nucleoporin of Plasmodium falciparum that is essential for parasite proliferation in human erythrocytes. Pt 14J. Cell Sci. 2013;126:3055&#x2013;3069. doi: 10.1242/jcs.122119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.122119</ArticleId><ArticleId IdType="pubmed">23687383</ArticleId></ArticleIdList></Reference><Reference><Citation>Gcanga L., Tamgue O., Ozturk M., Pillay S., Jacobs R., Chia J.E., Mbandi S.K., Davids M., Dheda K., Schmeier S., et al. Host-Directed Targeting of LincRNA-MIR99AHG Suppresses Intracellular Growth of Mycobacterium tuberculosis. Nucleic Acid Ther. 2022;32:421&#x2013;437. doi: 10.1089/nat.2022.0009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/nat.2022.0009</ArticleId><ArticleId IdType="pmc">PMC7613730</ArticleId><ArticleId IdType="pubmed">35895506</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachhawat N., Mande S.C. Identification of the INO1 gene of Mycobacterium tuberculosis H37Rv reveals a novel class of inositol-1-phosphate synthase enzyme. J. Mol. Biol. 1999;291:531&#x2013;536. doi: 10.1006/jmbi.1999.2980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jmbi.1999.2980</ArticleId><ArticleId IdType="pubmed">10448034</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Chen Z., Li X., Zhang H., Huang Q., Zhang Y., Xu S. Inositol-1-phosphate synthetase mRNA as a new target for antisense inhibition of Mycobacterium tuberculosis. J. Biotechnol. 2007;128:726&#x2013;734. doi: 10.1016/j.jbiotec.2006.12.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbiotec.2006.12.019</ArticleId><ArticleId IdType="pubmed">17275118</ArticleId></ArticleIdList></Reference><Reference><Citation>Skvortsova Y.V., Salina E.G., Burakova E.A., Bychenko O.S., Stetsenko D.A., Azhikina T.L. A New Antisense Phosphoryl Guanidine Oligo-2&#x2019;-O-Methylribonucleotide Penetrates Into Intracellular Mycobacteria and Suppresses Target Gene Expression. Front. Pharmacol. 2019;10:1049. doi: 10.3389/fphar.2019.01049.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2019.01049</ArticleId><ArticleId IdType="pmc">PMC6778816</ArticleId><ArticleId IdType="pubmed">31632266</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang J., Ye G., Shi K., Wan Y., Luo C., Aihara H., Geng Q., Auerbach A., Li F. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581:221&#x2013;224. doi: 10.1038/s41586-020-2179-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2179-y</ArticleId><ArticleId IdType="pmc">PMC7328981</ArticleId><ArticleId IdType="pubmed">32225175</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao Y., Wotring J.W., Zhang C.J., Jiang X., Xiao L., Watt A., Gattis D., Scandalis E., Freier S., Zheng Y., et al. Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection. PLoS ONE. 2023;18:e0281281. doi: 10.1371/journal.pone.0281281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0281281</ArticleId><ArticleId IdType="pmc">PMC9897518</ArticleId><ArticleId IdType="pubmed">36735698</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabani M.M., Gait M.J. miR-122 targeting with LNA/2&#x2019;-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates. RNA. 2008;14:336&#x2013;346. doi: 10.1261/rna.844108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1261/rna.844108</ArticleId><ArticleId IdType="pmc">PMC2212241</ArticleId><ArticleId IdType="pubmed">18073344</ArticleId></ArticleIdList></Reference><Reference><Citation>Groseth A., Charton J.E., Sauerborn M., Feldmann F., Jones S.M., Hoenen T., Feldmann H. The Ebola virus ribonucleoprotein complex: A novel VP30-L interaction identified. Virus Res. 2009;140:8&#x2013;14. doi: 10.1016/j.virusres.2008.10.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2008.10.017</ArticleId><ArticleId IdType="pmc">PMC3398801</ArticleId><ArticleId IdType="pubmed">19041915</ArticleId></ArticleIdList></Reference><Reference><Citation>Chery J., Petri A., Wagschal A., Lim S.Y., Cunningham J., Vasudevan S., Kauppinen S., N&#xe4;&#xe4;r A.M. Development of Locked Nucleic Acid Antisense Oligonucleotides Targeting Ebola Viral Proteins and Host Factor Niemann-Pick C1. Nucleic Acid Ther. 2018;28:273&#x2013;284. doi: 10.1089/nat.2018.0722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/nat.2018.0722</ArticleId><ArticleId IdType="pmc">PMC6425983</ArticleId><ArticleId IdType="pubmed">30133337</ArticleId></ArticleIdList></Reference><Reference><Citation>Li K., Zhou Z., Wang Y.O., Liu J., Zhao H.B., Yang J., Wang S.Q. Pretreatment of mice with oligonucleotide prop5 protects them from influenza virus infections. Viruses. 2014;6:573&#x2013;581. doi: 10.3390/v6020573.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v6020573</ArticleId><ArticleId IdType="pmc">PMC3939472</ArticleId><ArticleId IdType="pubmed">24509810</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J., Bo X.C., Ding X.R., Dai J.M., Zhang M.L., Wang X.H., Wang S.Q. Antisense oligonucleotides targeted against asialoglycoprotein receptor 1 block human hepatitis B virus replication. J. Viral Hepat. 2006;13:158&#x2013;165. doi: 10.1111/j.1365-2893.2005.00666.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2893.2005.00666.x</ArticleId><ArticleId IdType="pubmed">16475991</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko S.H., Huang L.M., Tarn W.Y. The Host Heat Shock Protein MRJ/DNAJB6 Modulates Virus Infection. Front. Microbiol. 2019;10:2885. doi: 10.3389/fmicb.2019.02885.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2019.02885</ArticleId><ArticleId IdType="pmc">PMC6917656</ArticleId><ArticleId IdType="pubmed">31921062</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko S.H., Liau Y.J., Chi Y.H., Lai M.J., Chiang Y.P., Lu C.Y., Chang L.Y., Tarn W.Y., Huang L.M. Interference of DNAJB6/MRJ Isoform Switch by Morpholino Inhibits Replication of HIV-1 and RSV. Mol. Ther. Nucleic Acids. 2019;14:251&#x2013;261. doi: 10.1016/j.omtn.2018.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2018.12.001</ArticleId><ArticleId IdType="pmc">PMC6330513</ArticleId><ArticleId IdType="pubmed">30641477</ArticleId></ArticleIdList></Reference><Reference><Citation>Gredell J.A., Berger A.K., Walton S.P. Impact of target mRNA structure on siRNA silencing efficiency: A large-scale study. Biotechnol. Bioeng. 2008;100:744&#x2013;755. doi: 10.1002/bit.21798.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bit.21798</ArticleId><ArticleId IdType="pmc">PMC2658823</ArticleId><ArticleId IdType="pubmed">18306428</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadhwa A., Aljabbari A., Lokras A., Foged C., Thakur A. Opportunities and Challenges in the Delivery of mRNA-based Vaccines. Pharmaceutics. 2020;12:102. doi: 10.3390/pharmaceutics12020102.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics12020102</ArticleId><ArticleId IdType="pmc">PMC7076378</ArticleId><ArticleId IdType="pubmed">32013049</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida T., Naito Y., Yasuhara H., Sasaki K., Kawaji H., Kawai J., Naito M., Okuda H., Obika S., Inoue T. Evaluation of off-target effects of gapmer antisense oligonucleotides using human cells. Genes. Cells. 2019;24:827&#x2013;835. doi: 10.1111/gtc.12730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/gtc.12730</ArticleId><ArticleId IdType="pmc">PMC6915909</ArticleId><ArticleId IdType="pubmed">31637814</ArticleId></ArticleIdList></Reference><Reference><Citation>Judge A., MacLachlan I. Overcoming the innate immune response to small interfering RNA. Hum. Gene Ther. 2008;19:111&#x2013;124. doi: 10.1089/hum.2007.179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2007.179</ArticleId><ArticleId IdType="pubmed">18230025</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22997875</PMID><DateCompleted><Year>2012</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0300-5038</ISSN><JournalIssue CitedMedium="Print"><Issue>163</Issue><PubDate><Year>2011</Year></PubDate></JournalIssue><Title>IARC scientific publications</Title><ISOAbbreviation>IARC Sci Publ</ISOAbbreviation></Journal><ArticleTitle>Infectious diseases.</ArticleTitle><Pagination><StartPage>421</StartPage><EndPage>440</EndPage><MedlinePgn>421-40</MedlinePgn></Pagination><Abstract><AbstractText>Molecular tools have enhanced our understanding of the epidemiology of infectious diseases by describing the transmission system, including identifying novel transmission modes and reservoirs, identifying characteristics of the infectious agent that lead to transmission and pathogenesis, identifying potential vaccine candidates and targets for therapeutics, and recognizing new infectious agents. Applications of molecular fingerprinting to public health practice have enhanced outbreak investigation by objectively confirming epidemiologic evidence, and distinguishing between time-space clusters and sporadic cases. Clinically, moleculartools are used to rapidly detect infectious agents and predict disease course. Integration of molecular tools into etiologic studies has identified infectious causes of chronic diseases, and characteristics of the agent and host that modify disease risk. The combination of molecular tools with epidemiologic methods provides essential information to guide clinical treatment, and to design and implement programmes to prevent and control infectious diseases. However, incorporating molecular tools into epidemiologic studies of infectious diseases impacts study design, conduct, and analysis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Foxman</LastName><ForeName>Betsy</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>University of Michigan School of Public Health, Ann Arbor, Michigan, USA. bfoxman@umich.edu</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>IARC Sci Publ</MedlineTA><NlmUniqueID>8009542</NlmUniqueID><ISSNLinking>0300-5038</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003141" MajorTopicYN="N">Communicable Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000635" MajorTopicYN="Y">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004198" MajorTopicYN="N">Disease Susceptibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017720" MajorTopicYN="Y">Molecular Epidemiology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22997875</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>